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INTRODUCTION 
 
THE p14ARF TUMOUR SUPPRESSOR. 
 
The ARF tumour-suppressor protein, also known as p14ARF in the 
human and p19ARF in the mouse, was identified as an alternative 
transcript of the INK4a/ARF locus that was previously shown to encode 
for p16INK4a, an inhibitor of the CDK4-CDK6 cyclin dependent 
kinases (Sharpless et al., 1999). The genetic alteration of this locus 
occurs at high frequency in a wide spectrum of human cancers such as 
glioblastoma, melanoma, pancreatic adeno-carcinoma, non-small cell 
lung cancer and bladder carcinoma (Sherr 1998, reviewed in Sharpless 
2005). 
Both human (p14ARF) and mouse (p19ARF) ARF are small and highly 
basic proteins, mainly localized in the nucleolus. They display no 
homology to other known proteins and share only 50% amino acid 
identity. The ARF proteins show significant sequence similarity within 
their 14 amino-terminal amino acids and this region retains many of the 
known ARF functions, including nucleolar localization, MDM2 binding 
and ability to induce cell cycle arrest. The carboxy-terminus of ARF also 
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encodes functional domain; in particular, the ability of ARF to promote 
the sumoylation of its binding partners involves the C-terminal nucleolar 
localization sequence of p14ARF (Xirodimas et al., 2002, reviewed in 
Gallagher et al., 2006). Furthermore, melanoma associated mutations 
targeting this functional domain impair the nucleolar localization and 
sumoylation activity of p14ARF (Rizos et al., 2005). 
The ARF oncosuppressor is among the most relevant oncogenic stress 
sensor in mammalian cells. In normal conditions, cells contain low levels 
of ARF but the expression of a variety of proliferation-promoting 
proteins, activates ARF as a part of checkpoint response that counters 
oncogenic signals by promoting cell cycle arrest or apoptosis through 
both p53-dependent and independent mechanisms.  
Interestingly, p19ARF was also found to be upregulated in senescent 
mouse fibroblast. In contrast, the human p14ARF does not appear to be 
required for the senescence process; p14ARF expression levels, in fact, 
remain low as cells near senescence (Sharpless 2005). The differential 
role of mouse and human proteins in promoting senescence may relate to 
differences in their regulation.  
Expression of p19ARF is induced by many oncogenes including c-Myc, 
adenovirus E1A, Ras, E2F1 and v-Abl (Sharpless 2004). Much less is 
known about the regulation of p14ARF expression. p14ARF 
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transcription is regulated by members of the E2F family (Parisi et al., 
2002), a group of transcription factor that control the expression of genes 
that are involved in cell cycle progression by acting either as 
transcriptional repressor, in conjugation with members of retinoblastoma 
family, or as transcriptional activator. The regulation of p14ARF gene by 
E2F results very particular and is different from that of classical E2F 
targets. p14ARF is not induced when fibroblasts re-enter the cell cycle 
following serum addition, as would be expected of an E2F-responsive 
gene. p14ARF only responds to aberrant levels of E2F ignoring the 
physiological fluctuations associated with cell-cycle progression (Figure 
1). This different regulation is mediated by a novel E2F-responsive 
element (EREA) in the ARF promoter that varies from the typical E2F 
site, discriminating abnormal growth signals due to ectopic expression of 
E2F1 from normal growth signals (Komori et al., 2005). Since E2F3 
maintains ARF promoter in repressed state when there is no oncogenic 
stress signal, the activating E2F must
 
somehow override or negate the 
repressive function of E2F3
 
to ensure ARF induction (Aslanian et al., 
2004).  
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Figure 1 Model for transcriptional regulation of the ARF gene expression by 
E2F. 
Deregulated E2F that arises through defective pRb function activates the ARF 
promoter through EREA independently of the cell cycle, whereas physiological E2F 
activity induced during the normal cell cycle cannot activate the ARF promoter. 
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Recently, it has been described a short form of the ARF tumour 
suppressor, whose translation begins from the internal methionine codon 
within both human and mouse (Met48 in p14ARF e Met45 in p19ARF). 
Also smARF levels were elevated in response to ectopic expression of 
viral and cellular oncogenes. These unstable proteins localize into 
mitochondria and are capable to trigger autophagy, a process usually 
initiated in response to nutrient starvation in which cells digest their own 
organelles, in an effort to derive energy (Reef et al., 2006). smARF, as 
well as the full-length version of the protein, does not contain lysines 
although is quickly degraded by the proteasome. 
 
p53-dependent activity of the p14ARF tumour-suppressor. 
ARF expression following aberrant oncogene activation leads to the 
induction of the p53-pathway. The ARF induction of p53 is mediated 
through two ubiquitin ligases, MDM2 and ARF-BP1/Mule (ARF-
binding protein 1/Mcl-1 ubiquitin ligase E3). Both MDM2 and ARF/BP1 
act as specific E3 ubiquitin ligase for p53, are highly expressed in 
various types of tumours, and have the potential to abrogate the tumour-
suppressor function of p53. 
MDM2 modulates p53 activity by directly blocking its transcriptional 
activation functions and by promoting its polyubiquitination and 
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proteasome-mediated degradation (Kamijo et al., 1998; Pomerantz et al., 
1998). ARF interacts with the central acidic domain (CAD) of MDM2 
(Bothner et al., 2001) and inhibits MDM2 E3 ligase function, resulting in 
p53 stabilization and consequent upregulation of p53 target genes, such 
as BAX and p21
Waf1
 (Midgley et al., 2000). In addition, ARF sequesters 
MDM2 in nucleoli, thus relieving nucleoplasmic p53 from MDM2-
mediated degradation. However, recent data, suggest that nucleolar 
relocalization of MDM2 is not required for p53 activation and that the 
redistribuition of ARF into the nucleoplasm enhances its interaction with 
MDM2 and its p53-dependent growth-suppressive function (Korgaonkar 
et al., 2005). 
In addition to MDM2, ARF-BP1 is a key regulator of the p53 cell cycle 
regulator pathway; ARF-BP1 directly binds and ubiquitinates p53 in an 
MDM2-independent manner. Silencing of ARF-BP1 extended the half-
life of p53, resulting in the transcriptional activation of p53 targets like 
p21
Waf1
 and BAX, and activating a p53-dependent apoptotic response 
(Chen et al., 2005). ARF-BP1 possesses both anti-apoptotic (via p53 
degradation) and pro-apoptotic (via Mcl-1 degradation) functions. 
Following aberrant oncogenic stimuli, ARF is induced and inhibits ARF-
BP1 activity toward p53 in the nucleus, thereby leading to p53 
dependent cell cycle arrest or apoptosis. In the cytoplasm, where ARF is 
Introduction 
10 
not present, oncogene activation may lead to ARF-BP1 mediated Mcl-1 
degradation (Figure 2). In this way ARF would act as a regulator keeping 
the balance between pro-apoptotic and anti-apoptotic functions.  
 
Nucleoplasm
Nucleolus
 
Figure 2 Proposed mechanism of ARF action. 
Aberrant oncogenics activation leads to ARF induction and increased rRNA 
transcription. Under these conditions ARF localizes predominantly in the nucleolus, 
where it is bound to B23. This complex may allow ARF to influence the programme 
of cell growth, at least in part, by inhibiting the processing of rRNA. When the cell 
undergoes to cytotoxic or genotoxic stress, B23 and ARF redistribuite to the 
nucleoplasm to complex with MDM2 and/or ARF-BP1. These binary complexes 
inactivate MDM2 and ARF-BP1 ubiquitine-ligase, causing p53 stabilization and 
leading to cell cycle arrest or cell death. 
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p53-independent activity of the p14ARF tumour-suppressor. 
Although it is generally accepted that much of ARF’s tumour-suppressor 
activity is mediated trough p53, a growing body of evidences suggests 
that ARF has also p53-independent function.  
First evidences came from ARF
-/-
 mice that develop carcinomas and 
neurogenic tumours rarely seen in p53
-/-
 mice. In addition, c-Myc-
induced lymphomas are more aggressive in ARF
-/-
 / p53
-/-
 mice 
compared to either p53
-/-
 or ARF
-/-
 alone (Eishen et al., 1999). Triple 
knock out mice nullizygous for ARF, p53 and MDM2 develop multiple 
tumours at higher frequency than that of mice lacking both p53 and 
MDM2 or p53 alone (Weber et al., 2000). Recently, it has been reported 
that tumours emerged significantly earlier in mice lacking both ARF and 
p53 than in the mice lacking p53 alone (Christophorou et al., 2006). 
One of the most streaking evidence of the antiproliferative p53 
independent activities of ARF is its involvement in ribosome biogenesis. 
ARF retards the processing of early 47S/45S and 32S rRNA precursors, 
as demonstrated in mouse cells (Sugimoto et al., 2003; reviewed in 
Sharpless 2005) and can inhibit the processing of ribosomal RNA 
through the direct binding to B23, an abundant nucleo/nucleolar 
endoribonuclease that plays a key role in the ribosome biogenesis. B23 
overexpression induces the cells in mitosis whereas its silencing causes 
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cell cycle arrest. ARF causes B23 proteasomal degradation by increasing 
its ubiquitination rate and bringing to an inhibition of rRNA processing 
(Itahana et al., 2003; Bertwistle et al., 2004).  
Several studies also have linked the antiproliferative functions of ARF to 
its capability to strongly inhibit the HIF-1 (hypoxia indicible factor-1) 
transcription factor. This effect requires the binding to HIF-1α and its 
nucleolar relocalization (Fatyol et al., 2001). The alpha subunit of HIF-1 
was found to be frequently overexpressed in advanced tumours.  
Another p53-independent effect particularly interesting regards the 
negative regulation of transcription factor such as E2F1 and c-Myc. ARF 
expression causes relocalization of  E2F1 from the nucleoplasm to the 
nucleolus inducing its degradation through the ubiquitin-proteasome 
pathway (Martelli et al., 2001; Eymin et al., 2001). Moreover, ARF 
binds to c-Myc, relocalizes its in the nucleolus and blocks c-Myc ability 
to activate transcription and induce hyperproliferation and 
transformation (Datta et al., 2004). 
The p53-independent tumour-suppressive function of ARF can be also 
mediated by its ability to enhance sumoylation of many protein targets. 
Sumoylation is analogous to ubiquitination, and is the process by which 
the SUMO (small ubiquitin-like modifier) protein is conjugated to a 
target protein. Effect of sumoylation are highly diverse and can influence 
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protein transport, modulation of gene expression, DNA repair and 
centromeric chromatid cohesion. ARF promotes sumoylation of its 
binding partners acting as an adaptor molecule, which recruit E2-SUMO 
conjugative enzyme Ubc9 to their substrates (Tago et al., 2005). Until 
now, only for B23 it is possible to associate a biological effect of 
sumoylation mediated by ARF: the increase of sumoylation, in fact, 
brings to a deep impact on B23 activity inside the cell affecting its 
subcellular localization, cellular proliferation and survival (Liu et al., 
2007). Recent studies have demonstrated that ARF can increase 
sumoylation of B23 controlling the stability of the nucleolar SUMO-2/3 
deconjugating enzyme SENP3 (Kuo et al., 2008). In particular, ARF 
promotes phosporylation dependent ubiquitination and proteasomal 
degradation of SENP3. Interestingly, the ability of ARF to accelerate 
SNP3 turnover also depends on the presence of B23. Conversely, the 
association of SENP3 with B23 can counteract the effect of ARF by 
deconjugating SUMO from B23. These observations suggest that ARF 
and SNP3 antagonize each others’ s functions and that B23 acts as a 
“platform” for both the proteins, bringing in close proximity its two 
regulators. 
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Antiviral action of the ARF tumour suppressor. 
While it is clear that p53 is involved in the antiproliferative and antiviral 
effects of IFNs and viral infection (Takaoka et al., 2003), the role of 
ARF, one of the most important activators of p53, in the viral response, 
only recently has been highlighted. 
The first evidence came from the group of Sandoval (2004). They found 
that type I interferon up-regulates p53 via ARF, as demonstrated by the 
absence of p53 induction in ARF-/- mouse embryonal fibroblasts 
(MEFs) and in ARF null human U2OS cells. Interestingly, they showed 
an increase in ARF expression following treatment of SAOS cells (p53-
/-) with interferon or viral infection, leading to the hypothesis that ARF 
can act as antiviral also in a p53-independent pathway. 
The role of ARF as a sensor of viral stress was also demonstrated by the 
group of Garcia (2006). They analysed the cytopathic effect caused by 
VSV (vescicular stomatitis virus) infection of MEFs derived from 
animals with different ARF gene dosage and observed a clear ARF 
dosage dependent protection against viral infection. This antiviral action 
is mediated, at least in part, through the inhibitory effect that ARF exerts 
on one of its main molecular partner, NPM/B23, involved in the 
repression of the double-stranded RNA-dependent protein kinase, PKR, 
one of the principle effectors of the antiviral response. The final effect is 
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an ARF-induced release and activation of PKR from B23 complexes that 
leads to VSV attenuation.  
 
ARF regulates the protein turnover and function of most of its 
interacting partners. 
ARF response is exerted through the activation of complex signalling 
networks accomplished by the interaction with a multitude of different 
cellular partners. During the last years many efforts have been attempted 
in search of ARF partners that could partly explain the p53-MDM2 ARF 
independent functions.  
In addition to its first “spouse” MDM2, the ARF interactors “harem” 
consists of something like 30 different proteins involved in various 
cellular activities (Figure 3): proteins involved in transcriptional 
control, such as E2Fs, DP1, c-myc, p63, HIF1, Foxm1b, nucleolar 
proteins such as nucleolin/C23 and nucleophosmin (NPM/B23), viral 
proteins such as HIV-1Tat, proteins involved in copper metabolism like 
COMMD1, proteins involved in chromosomal stability and/or 
chromatin structure such as Topoisomerase I, Tip60, and WRN helicase, 
ubiquitin ligases like Ubc9 (the E2 ligase required for sumoylation), 
MDM2 and ARF-BP1/Mule, (E3 ubiquitin ligases).  
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Although the actual mechanism by which ARF affects the function of its 
partners is still unclear, the functional consequence is, quite invariably, 
inactivation (Lowe et al., 2003).  
For some targets, ARF interaction causes alteration of stability. For 
example, B23/NPM and E2Fs become degraded by the proteasome in a 
ubiquitin-dependent manner, while the CtBP2 antiapoptotic 
transcriptional co-repressor and HIV-1 Tat become degraded by the 
proteasome in a ubiquitin-independent manner. Other targets changes 
their localization like E2Fs, c-myc, Foxm1b, MDM2, ATR, DP-1, Hif1 
upon ARF expression. Only few others, like Tip60, Topo I and 
COMMD1 become activated or stabilized. Finally, most of the partners 
become sumoylated although a precise function to this modification has 
not yet been assigned (Rizos et al., 2005).  
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Figure 3 Some of the ARF interactors “harem”. 
Orange is for partners whose activity is blocked by ARF. Red is for partners that are 
induced to proteasome and ubiquitin dependent degradation by ARF. Pink is for 
partners that are induced to proteasome dependent, ubiquitin independent 
degradation by ARF. Green is for partners whose activity or stability are positively 
regulated by ARF. Blue is for partners that regulate ARF protein turnover. A second 
black circle indicates nucleolar sequestration.  
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Particularly interesting is the inhibitory effect that ARF exerts on 
oncogenes such as members of the E2F family, required for cell-cycle 
progression and to mediate ARF oncogenic activation, suggesting a 
potential role of these interactions as being part of a negative feedback 
loop.  In a series of reports ARF was shown to interact with E2F1, and 
this interaction prevented the formation of active E2F1 transcritional 
complexes (Datta et al., 2002), inhibited E2F1 transactivation potential 
(Eymin et al., 2001) and promoted the proteasome dependent 
degradation of E2F1 (Martelli et al., 2001). The regulation of the ARF-
dependent E2F1 turnover by the proteasome appears to involve E2F1 
ubiquitination (Rizos et al., 2007), although the genetic context in which 
this process occur is not yet completely clear.  
In line with a role of ARF in promoting ubiquitin dependent degradation 
of its partners is the observation that NPM/B23, is a molecular target of 
ARF. The vast majority of ARF appears localized in nucleoli, tightly 
associated with NPM/B23. Interestingly, the ARF-B23/NPM interaction 
seems critical in the regulation of both proteins (Korgaonkar et al., 2005; 
Enomoto et al., 2006). Under normal conditions, B23 appears to retain 
ARF in the nucleolus, retarding its turnover. Indeed, the stability and 
nucleolar localization of ARF is markedly reduced in cells lacking NPM 
and leukemia-associated NPM mutants are unable to stabilize ARF 
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(Colombo et al., 2006). However, ARF hyper-expression induces B23 
proteasomal degradation by increasing its ubiquitination rate and 
proteasomal degradation bringing to an inhibition of rRNA processing 
(Itahana et al., 2003). These observations lead to the conclusion of the 
existence of a regulative loop between ARF and B23, in which 
degradation and inhibition of both proteins is finely and tightly 
modulated by external stimuli. In such a situation, ARF serves a dual 
function to restrain both growth and proliferation. 
Interestingly, ARF appears to mediate also ubiquitin-independent 
degradation of the antiapoptotic transcriptional corepressor C-terminal 
Binding Protein 2 (CtBP2). CtBP2 is degraded by the proteasome after 
UV exposure leading to apoptosis in colon cancer cells (Zhang et al., 
2003). It has been shown that UV induced CtBP2 degradation by the 
proteasome is dependent on ARF intracellular protein levels. Moreover, 
human ARF hyper-expression without UV stimulation, resulted in 
proteasome mediated degradation of CtBP2, not accompanied by an 
appreciable increase in CtBP2 ubiquitination (Paliwal et al., 2006) 
although CtBP2 is ubiquitinated in the cells used. Still open is the 
possibility that the experimental system used was not enough sensitive to 
detect changes in the levels of ubiquitination. 
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p14ARF has also been shown to mediate the proteasome-dependent, 
ubiquitin independent degradation of the HIV1-Tat protein (Gargano et 
al., 2008). Interestingly, MDM2 has been shown to ubiquitinate HIV1-
Tat, although, in this case, ubiquitination determines an increase of the 
Tat-mediated transactivation properties (Bres et al., 2003). This lead to 
the speculation that ARF could act on HIV-1Tat in two ways: directly 
mediating its degradation and/or inhibiting the MDM2 activity versus 
Tat, thus blocking viral transcription. This hypothesis would intriguingly 
fit with the ARF role in viral defence (Garcia et al.,  2006). 
As mentioned above, in some cases, ARF is able to stabilize its partners 
from proteasomal degradation. In a quite recent study, it has been 
described the ARF’s ability to induce a non-classical polyubiquitination 
of a new interacting partner, the COMMD1 factor 60, a multifunctional 
protein involved in copper metabolism and apoptosis. While in normal 
conditions COMMD1 is degraded by the proteasome, ARF coexpression 
leads to a stabilization of the protein through its poly-ubiquitination on 
K63 lysine of the ubiquitin peptide. K63 is distinct from the classical, 
K48-linked ubiquitination, usually involved in protein degradation. 
Interestingly, most neurodegenerative diseases like Parkinson disease, 
are marked by the presence of ubiquitin-positive protein inclusions that 
escape proteasomal degradation despite being enriched with ubiquitin:  it 
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has been observed that K63 polyubiquitination plays a role in this 
stabilization (Lim et al., 2005).  
Altogether, although these observations do not explain the molecular 
mechanisms of ARF effects on many of its targets, they reinforce the 
idea that its antioncogenic activity could be partly exerted through the 
cellular degradation machinery.  
In this sense ARF interaction with the proteasome could serve dual roles: 
on one side it is necessary to regulate ARF protein turnover, on the other 
side it could play a role in bringing its interacting partners to the 
ubiquitin/proteasome machinery (Pollice et al., 2008). 
 
ARF intracellular levels are regulated by the proteasome. 
The proteasome is the chief site of protein destruction in eukaryotic 
cells. It is made by the dynamic, ATP-dependent association of the 20S 
catalytic proteasome (made by four stacked heptameric rings) with the 
regulatory 19S subunit that sits as a "collar" on one or both ends of the 
20 S proteasome -although “free” 20S as well as 19S caps can be found 
in the cell (Hershko et al., 1998; Adams et al., 2004). 19S regulatory 
subunit is composed of a “base” (with ATPase activity) that binds 
directly to the 20S core particle, and a “lid” that usually contacts 
substrates that have to be degraded. Protein proteolysis requires 
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recognition of the substrate, its unfolding and translocation into the 
cavity of the 20S proteasome. Ubiquitinated proteins are sent to the 20S 
catalytic barrel-shaped proteasome core by ubiquitin dependent binding 
to the 19S particles whose function is to open the barrel and allow 
protein entry.  
On the other hand, non ubiquitinated proteins can also be degraded by 
the 20S proteasome, as well as by the 26S proteasome itself (Kalejta et al 
2003; Asher et al., 2005). Nonetheless, the mechanism by which 
proteasomes recognize proteins in the absence of ubiquitination is not 
understood and appear to mainly regard small, unstructured proteins that 
can gain direct access to the core proteasome without the need for a 
specific interaction mechanism. 
Activation of the proteasome can be achieved also by binding of the 11S 
(also called REG or PA28) regulator that, alternatively to the 19S, 
triggers the “opening of the gate”. The REG/11S particle can be found, 
as the 19S proteasome, independent or associated with 20S proteasomes 
as a heptameric lid and participate to its activation in an ATP-
independent fashion. The REG family of activators has three members: 
REG and REG subunits, mainly localized in the cytoplasm, enriched 
in the endoplasmic reticulum, usually involved in the MHC class I 
antigen presentation, and REG primarily residing in the nucleus 
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(Slaughter et al., 1992; Realini et al., 1997). -interferon treatment 
appears to induce an increase in the levels of REG and REG subunits, 
but not a change in their localization. The REG function is still largely 
elusive although knock out mice suggest a role in the regulation of 
mitosis and apoptosis (Barton et al., 2004; Zannini et al 2008). Recently 
it has been isolated a chimerical form of the proteasome composed by 
both the regulative subunits, whose function is not yet known (Figure 4).  
The first evidence of a link between ARF and the proteasome is the 
observation that both human and mouse ARF accumulate following 
treatment with proteasome inhibitors suggesting that ARF degradation 
depends, at least in part, by the proteasome (Rodway et al, 2004; Kuo et 
al., 2004; Pollice et al., 2007).  
For the vast majority of proteins, conjugation of ubiquitin to internal 
lysines is the initial event in their degradation by the ubiquitin-
proteasome system. However, the human p14ARF protein is lysine-less 
and the murine p19ARF has a single lysine residue whose ubiquitination 
is not required for its proteasome degradation (Kuo et al. 2004). The 
same author observed that ARF can be subjected to N-terminal 
ubiquitination, a process described in engineered lysine-less mutants of 
certain viral and cellular proteins and that this process appears 
independent from p53 and MDM2. 
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/ REG
20S/11S
 
Figure 4 Structure of the proteasome. 
The 20S catalytic proteasome can associate with one or two 19S regulative subunit 
giving rise to the 26 proteasome, mainly involved in the degradation of ubiquitinated 
proteins or with the 11S/REG subunit. 
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The N-terminal ubiquitination is strictly dependent by the sequence of 
N-terminal amino acids. The vast majority of eukaryotic proteins are 
acetylated at their N-termini, being acetylation and ubiquitination two 
processes in competition with each other. Generally, basic residues 
inhibit acetylation but favour ubiquitination. Examination of the ARF N-
termini (human: Met-Val-Arg; mouse: Met-Gly-Arg) predicts that they 
should be processed by methionine aminopeptidases (methionine is a 
good substrate for acetylation but when followed by small amino acids it 
is cut by a specific amino peptidases) and that acetylation of valine and 
glycine should be strongly inhibited by the penultimate arginine residue. 
However, other authors do not report ubiquitination of the protein but 
claim the importance of MDM2 in ARF proteasome degradation. 
Gordon Peters’s group (2004) investigated on the effects of ARF 
subcellular localization on its turnover and demonstrated that the 
stability of ARF can be enhanced by redirecting it to the nucleolus, by 
depleting the cells of MDM2 or by inhibiting proteasome functions, 
suggesting a model in which ARF associates with MDM2 in the 
nucleoplasm and is consequently subjected to rapid degradation. The 
ARF binding to MDM2 could explain why it is difficult to visualize 
ARF in the nucleoplasm, where it would be vulnerable to MDM2-
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mediated degradation. Thus, in binding to MDM2 and blocking its E3 
ubiquitin-ligase activity towards p53, ARF committees a “suicide”.  
Interestingly, a very recent report has described a direct involvement of 
the REG proteasome in a ubiquitin-independent regulation of the ARF 
turnover (Figure 5). The demonstration that REG governs the turnover 
of ARF and of other important cell-cycle regulators like p21cip and 
p16INK4a, suggests that the REG pathway represents a new important 
mechanism to control protein turnover (Chen et al, 2007). These 
observations lead to the hypothesis that this pathway could be 
specialized for the proteasomal degradation of small unstructured 
proteins since p19ARF, p21, and p16 are all unstructured when not 
associated with specific binding partners (such as cyclins and Cdks, for 
p21 and p16, and nucleophosmin in the case of p19ARF), in agreement 
with previous data suggesting a role for REG only in the degradation of 
short peptides. However, the REG ubiquitin-independent mediated 
proteolysis of the oncogenic protein SRC-3 (Steroid receptor 
coactivator-3) challenged the idea that REG is involved only in the 
degradation of substrates with disordered elements (Zhou et al., 2006; Li 
et al., 2007). An interesting possibility is that the feature of proteins 
targeted to the REG pathway is the lack of ubiquitination, usually due 
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to the lack of lysine residues. Both p16 and human p14ARF are naturally 
lysine-less proteins and p21 and SRC-3 can be degraded in the absence 
of ubiquitination. Interestingly, viral proteins constitute a substantial 
subset of naturally lysine-less proteins. This raises the hypothesis that the 
REG pathway might play a role in the control of viral pathogenesis. 
This is very interesting, since ARF activation has been linked to viral 
response (Garcia et al., 2006).  
In this scenario, it is particularly intriguing our observation that one of 
the ATPases, component of the 19S proteasome, TBP-1, interacts with 
p14ARF but, unexpectedly, instead of bringing it to degradation, it is 
involved in its stabilization (Pollice et al., 2004 and 2007).  
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TBP-1, A MULTIFUNCTIONAL PROTEIN MEMBER OF 
THE 19S SUBUNIT OF THE PROTEASOME. 
 
TBP-1 (Tat- Binding Protein 1), is transcribed from the PSMC3 locus 
that maps at the 11p12-13 region. Deletions of this region is present in 
many types of tumours (Hoyle et al., 1997). 
Interestingly, mouse embryo knock out for the PSMC3 gene die before 
implantation and display defective blastocyst development suggesting 
the importance of the TBP-1 protein in the early phases of the 
embryogenesis and more in general for the cellular survival (Sakao et al., 
2000). 
TBP-1 is a member of a large conserved gene family of six ATPases 
(ATPAses Associated to a variety of cellular Activities) whose key 
feature is a highly conserved module of 230 amino acids consisting of an 
ATPase and a DNA/RNA helicase motif. Despite the sequence 
conservation, members of this protein family fulfill a large diversity of 
cellular functions including cell cycle regulation, gene expression, 
vesicle mediated transport, peroxisome assembly, and proteasome 
function. Indeed, as other members of the family, (MSS1/Rpt 1, 
S4/Rpt2, TBP-7/Rpt3, SUG2/Rpt 4, SUG1/Rpt 6 and Rpt5/TBP-1), 
TBP-1 is associated with the 19S regulatory subunit of the proteasome, 
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the chief site of protein destruction in eukaryotic cells (Figure 5). 
Consistent with this assumption, TBP-1, as well as the other 19S 
subunits, seems to recognize polyubiquitinate substrates and is involved 
in both the unfolding of target proteins and their subsequent 
translocation into the 20S proteolytic core. 
TBP-1 was originally isolated in a screen for proteins interacting with 
the HIV1-Tat protein and it has been demonstrated to suppress Tat-
mediated transactivation of HIV1 gene expression (Nelbock et al., 1990). 
More recently, it has been clarified the involvement of all six AAA-
ATPases in the control of transcription elongation of the HIV1 
transcriptome. TBP-1, although unable to bind DNA, is a strong 
transcriptional activator when brought into proximity of several 
promoter elements. Transcriptional activity depends upon the integrity of 
ATPase and helicase motifs (Ohana et al., 1993). 
TBP-1 exerts a more general role on transcription, demonstrated by its 
activity in stimulating HBx-specific transcription of the HBV virus 
(Barak et al., 2000). 
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Figure 5 Structure of TBP-1.  
TBP-1 belongs to the AAA-ATPases gene family and, as well as other members of 
this family, is part of the 19S subunit of the proteasome. 
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Roles other than proteolysis of TBP-1 and of the 19S subunits of 
the proteasome. 
Besides their role in proteolysis of ubiquitinated or non ubiquitinated 
proteins, many different reports have highlighted the involvement of 19S 
subunit protein members in cellular events that do not require 
proteolysis. In particular, it has been largely demonstrated that 19S 
subunits play a key role in the transcriptional regulation, acting at 
different levels: co-activators recruitment, mRNA elongation, initiation 
of transcription. 
The first evidences were obtained in yeast, where by chromatin 
immunoprecipitation assay was demonstrated the association between 
the Sug1 and Sug2 proteins with the promoters of Gal1/10 genes, upon 
induction with galactose (Gonzalez et al., 2002). 
The group of Ferdous (2002) reported that 19S subunits are critical for 
efficient elongation of RNA pol II. Antibodies against Rpt6, the 
mammalian analogue of Sug1 in yeast, abolish activated, but not basal, 
transcription in HeLa nuclear extract. In addition, immunodepletion of 
the 19S complex from a crude nuclear extract significantly reduces 
activated but not basal transcription. Furthermore, experiments using 
chemical inhibitors of proteasome-mediated proteolysis suggest that 19S 
requirement in transcription does not reflect a proteolytic event. 
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Sulahian and co-workers (2006), demonstrated that the proteasomal 
ATPases Sug1 and Sug2 (respectively Rpt6 and Rpt4 in mammalian) are 
essential for efficient transcription of several stress-induced genes in 
yeast. These include both heat shock and oxidative stress-responsive 
genes. When Sug1 or Sug2 activity was abolished by shifting 
temperature-sensitive strains to the restrictive temperature, transcription 
of these genes was crippled. In contrast, inactivation of temperature-
sensitive 20S core proteins had little or no detectable effect on 
expression of these genes. Furthermore, ChIP assay revealed the 
induction-dependent recruitment of the proteasomal ATPases, but not of 
the 20S core complex, to the promoter of these genes. In summary, the 
proteasomal ATPases are essential for the efficient transcription of many 
stress response genes through direct association with their promoter. 
Evidence that further support the notion that roles other than proteolysis 
could be feature of the 19S regulatory subunits of the  proteasome was 
the interaction of the  proteasome with the ubiquitin-like N-terminus of 
Rad23, a nucleotide excision repair (NER) protein, in S. cerevisiae 
(Russell et al., 1999). Deletion of the ubiquitin-like domain causes UV 
radiation sensitivity. Rad23 is required for optimal activity of an in vitro 
NER system. Inhibition of proteasomal ATPases diminishes NER 
activity in vitro and increases UV sensitivity in vivo. Surprisingly, 
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blockage of protein degradation by the proteasome had no effect on the 
efficiency of NER.  
 
Involvement of the proteasome in cancerogenesis. 
Abundant evidences suggest that a unifying principle governing the 
molecular pathology of cancer is the co-dependent aberrant regulation of 
core machinery driving proliferation and suppressing apoptosis. These 
cellular processes are, in part, regulated through the degradation of key 
regulatory proteins, whose abnormal turnover can contribute to tumour 
formation. On the other hand, anormal expression levels of proteasome 
have been described in many tumour cells and proteasome plasma levels 
appear elevated in neoplastic patients (Lavabre-Bertrand et al., 2001; 
Bazzaro et al., 2006). Thus, the “proteasome pathway” often appears to 
be the target of cancer-related deregulation and is involved in processes 
such as oncogenic transformation, tumour progression, escape from 
immune surveillance and drug resistance. Recently, it has been reported 
that gankyrin, an oncogene overexpressed in human hepatocellular 
carcinoma interferes with the proteasome activity; in fact this oncogene 
causes the pRB transcription factor degradation and the activation of the 
E2F family transcription factor with a mechanism similar to that of viral 
oncoprotein E7, that is, through the interaction with the ATPases 
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subunits. The gankyrin interacts with the TBP-1 subunit, whereas E7 
binds to S4/Rpt2. Both these interactions cause an increase of the pRb 
degradation rate and subsequent increase of the cellular proliferation 
(Higashitsuji et al., 2000). 
The HEC protein (Highly Expressed in Cancer) specifically interacts 
with the S7 ATPase and would be able to inhibit its ATPase activity. The 
result of this interaction causes a modulation of proteasome activity and 
prevents the degradation of the A and B cyclin, necessary for the 
progression of the cell cycle from the G2phase to the M phase (Chen et 
al.,1997).  
 
TBP-1 and its potential role in the control of cellular 
proliferation. 
A very interesting aspect of TBP-1 regards it possible role as tumour-
suppressor. The first evidence underlying the involvement of TBP-1 in 
the control of cellular proliferation came from Park and its co-workers 
(1999). They demonstrated that TBP-1 mRNA levels were up-regulated 
following inhibition of the oncogenic phenotype of transformed cells 
expressing erbB family receptor. Moreover, TBP-1 overexpression 
diminished cellular proliferation and reduced the ability of parental cells 
to forms colonies in Colony Formation Assay (Pollice et al., 2004). 
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TBP-1 also possesses 46% identity to KAI I, a metastasis tumour 
suppressor gene for human prostate cancer (Dong et al., 1995) and maps 
to chromosome 11p12-13, a region frequently deleted in cancers (Hoyle 
et al., 1997). 
Furthermore, it has been showed that TBP-1 binds to the tumour 
suppressor pVHL (Von Hippel Lindau), that results inactive in von-
Hippel-Lindau disease, an autosomal hereditary cancer syndrome 
characterized by the development of vasculars tumours in the retina and 
in the central nervous system and renal cell carcinoma. This association 
contributes to VHL-E3 ubiquitin ligase function toward the Hif1-α 
factor, highly overexpressed in cancer cells that have to sustain growth 
in low oxygen concentration. In normoxic conditions, TBP-1 binds to 
VHL and stimulates its ubiquitin ligase activity towards Hif1-α that is 
rapidly degraded by the proteasome (Figure 6). The interaction between 
TBP-1 and VHL is crucial since increased expression of TBP-1 resulted 
in enhanced kinetics degradation of Hif-1α whereas its silencing impairs 
the VHL-mediated proteasome degradation. Interestingly, tumour 
derived mutants of VHL, able to ubiquitinate Hif-1α but unable to bind 
to TBP-1 show delayed degradation rate of Hif-1 suggesting the 
essential function of TBP-1 in Hif-1 destruction and underlying the 
potential anti-tumoural activity of TBP-1. 
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In the last years, we highlighted a very interesting aspect of TBP-1 
concerning its role on the regulation of the p14ARF oncosuppressor 
intracellular levels. TBP-1 interacts with and regulates intracellular 
protein levels of p14ARF increasing its half life. This effect requires the 
physical interaction between the two proteins and does not involve the 
transcriptional properties of TBP-1; in fact, the relative level of ARF 
mRNA was similar in the presence or absence of TBP-1, and the mutant 
of TBP-1 that lacks the helicase domain, reported to be essential for the 
transcriptional activity, is still able to increase ARF levels (Pollice et al., 
2004).  
Thus, TBP-1 appears to serve a role in the control of cell proliferation 
either through the increase of degradation of an oncogene or the 
stabilization of an oncosuppressor. 
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Figure 6 TBP-1 is involved in the degradation of Hif1. 
(A) In cells with wild-type pVHL, pVHL forms a complex with Hif1 and TBP-
1.This complex allows for the efficient ubiquitination and degradation of Hif1by the 
proteasome. 
(B) pVHL mutants that do not interact with TBP-1 are able to bind and ubiquitinated 
Hif1 but have impaired degradation of Hif1 because of a failure of the pVHL-
Hif1 complex to interact with TBP-1 and the proteasome machinery. 
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PRELIMINARY DATA AND AIM OF THE THESIS 
 
In our laboratory it has been demonstrated that TBP-1 (Tat-Binding 
Protein 1), one of the six AAA-ATPases, component of the 19S subunit 
of the proteasome, interacts with and stabilizes the p14ARF 
oncosuppressor, delaying its turnover. This effect requires the physical 
interaction between the two proteins and does not involve the 
transcriptional properties of TBP-1 (Pollice et al., 2004, 2007).  
As component of the 19S base of the proteasome, TBP-1 should be 
involved in the recognition of substrates that have to be degraded, their 
unfolding and subsequent translocation into the 20S proteasome. Thus, 
the effect on ARF was somehow unexpected and intriguing at the same 
time. Importantly, this effect seems to be not dependent on the 
proteasome functions.  
Interestingly, the potential oncosuppressive role of TBP-1 appears not to 
be restricted to the effect on ARF as we and others (Pollice et al., 2004; 
Park et al., 1999; Corn et al., 2003) have observed that TBP-1 
overexpression can inhibit cell proliferation in various cellular contexts 
also independently by the presence of ARF. These observations not only 
further underlie the potential antiproliferative role of TBP-1 but suggest 
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that it can exert a more general ARF-independent role in the control of 
cell proliferation and raise the question of what kind of cellular signals 
modulate TBP-1 expression.  
During my thesis I sought to investigate on the potential antioncogenic 
role of TBP-1, on one side, studying the stabilization effect exerted on 
p14ARF and, on the other side, analyzing the antiproliferative role 
exerted by TBP-1 per se trying to unravel the molecular pathways 
involved. 
 The mechanisms governing ARF’ s turnover are not yet completely 
clarified, being ARF a lysine-less and a relatively stable protein (see 
Introduction), unstructured and largely disorder in solution (Bothner et 
al., 2001). I concentrated my efforts to gain more insights into the 
mechanism involved in the ARF’ s turnover, and I studied the 
involvement of the 20S proteasome in the regulation of ARF protein 
levels in the absence of ubiquitination and without the requirement of 
ATP. Furthermore, I investigated on the potential mechanism through 
which TBP-1 acts on ARF, analyzing the role of the physical interaction 
between the two proteins -by making use of various deletion mutants- 
and testing a model in which the TBP-1 chaperone activity causes ARF 
to fold becoming a poor substrate for proteasome destruction.  
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In the second part of my thesis I focused my research activity on the 
potential role of TBP-1 in the control of cell proliferation. I made use of 
primary human fibroblasts immortalized cell derivatives constitutively 
expressing an shRNA specifically designed to silence TBP-1 expression. 
It has been observed that the clones in which TBP-1 expression was 
silenced proliferate at higher rate respect to the control also in conditions 
of serum deprivation, display an increase of the S-phase and are more 
resistant to serum starvation induced apoptosis. These observations led 
me to look for the possible intracellular pathways involved. I observed 
that, in agreement with a potential tumour suppressive function, the 
cellular levels of TBP-1 appear critical to control cell duplication and are 
tightly regulated by a double-negative feedback loop that is mediated by 
the activation of the PKB/Akt kinase, one of the major transducers of 
cell survival and apotosis, that thus acts as a sensor to modulate the TBP-
1 levels in actively duplicating cells. Although the players of these 
molecular pathways have not yet to be identified, these studies open up 
interesting questions on the intracellular role of TBP-1, a multifunctional 
protein with yet undiscovered antioncogenic properties. 
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RESULTS 
 
ROLE OF TBP-1 IN THE CONTROL OF p14ARF LEVELS. 
 
TBP-1 regulates ARF intracellular levels. 
In our laboratory it has been demonstrated that TBP-1 (Tat- Binding 
Protein-1),  a multifunctional protein component of the 19S regulatory 
subunit of the proteasome, interacts with and regulates ARF protein 
levels increasing its half-life (Pollice et al., 2004). To further investigate 
on the importance of TBP-1 in controlling p14ARF steady-state levels, I 
have reduced endogenous TBP-1 protein levels by making use of RNA 
interference. To this aim I used human lung carcinoma H1299 cells, that 
present high levels of both ARF and TBP-1 to transfect them with a 
siRNA duplex designed to specifically silence TBP-1 expression. At 72 
hours after transfection, protein extract were prepared and protein 
concentrations determined using the Bio-Rad protein assay. Western blot 
of whole cell extracts and specific immunodetection with anti-TBP1 
antibodies and anti-ARF antibodies clearly show that reduction in 
endogenous TBP-1 protein expression results in a remarkable decrease 
of ARF intracellular levels, confirming that basal TBP-1 levels are 
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important in controlling basal p14ARF levels (Figure 1). It is interesting 
to note that silencing of TBP-1 in cells expressing wild-type pVHL leads 
to degradation of the Hif1α transcription factor (Corn et al., 2003). On 
the other hand, I did not observe any change in the basal expression 
levels of various cellular proteins (p21, Itch, Mdm2, B23/NPM, actin 
and -tubulin) (Figure 1). As some of them are reported to be subjected 
to proteasomal degradation, I concluded that reduction of TBP-1 
intracellular levels does not generally affect proteasome function, but 
rather appears to affect only specific targets. 
siRNA:
-TBP-1
-ARF
- B23
- actin
-Itch
100M
siRNA duplexes
10 M
siRNA duplexes
-TBP-1
- ARF
-  tubulin
- p21
- Mdm2
10 M
siRNA duplexes
 
Figure 1 Effect of TBP-1 silencing. 
H1299 cells were transfected with 10 M and 100 µM of a 21 bp TBP-1 siRNA or 
firefly luciferase siRNA. Western Blot analysis show expression levels of TBP-1, 
p14ARF and of other endogenous proteins at 72 hours after transfection. 
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The first N-terminal 39 amino acids in p14ARF are necessary 
for both interaction with and stabilization by TBP-1. 
We have already demonstrated that the interaction between ARF and 
TBP-1 in yeast requires the first  38 amino acids of ARF (Pollice et al., 
2004). To confirm these results also in mammalian cells, I have 
performed experiments of coimmunoprecipitation using, as a first 
attempt, a deletion mutant of ARF, lacking the first 39 amino acids (for 
the construction of the mutant see materials and methods). To this 
purpose, I have transfected U2OS cells, a human osteosarcoma cell line 
(devoid of ARF expression), with the pcDNAARF or pcDNA ARF39-132 
plasmids alone or in combination with the pcDNATBP-1. Cellular 
extracts were immunoprecipitated with antibodies against either TBP-1 
or ARF, run on a SDS-Page, blotted and incubated with anti His (to 
reveal TBP-1) and anti ARF antibodies. As shown in figure 2, wtARF, 
as expected, interacts with TBP-1 whereas the deletion of the first 38 
amino acids impairs the ability of ARF to bind to TBP-1. 
To confirm that the 1-39 N-terminal region of ARF was strictly 
necessary for the interaction with TBP-1, I used the pCMV 3xFlag 
ARF1-39 in coimmunoprecipitation (CoIP) experiments. As controls, I 
included the 3xFlag ARF1-65 and the 3xFlag ARF65-132 plasmids, kindly 
provided by Prof. Barbara Majello. Cellular extracts were 
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immunoprecipitated with antibodies against TBP-1, run on SDS-Page, 
blotted and incubated with anti-His (to reveal TBP-1) and anti-Flag (to 
reveal ARF). As shown in figure 3 TBP-1 can interact only with the 
ARF deletion mutants that retain either sequences corresponding to exon 
1β (3xFlag ARF1-65) or to the first 39 amino acids (3xFlag ARF1-39). 
These experiments demonstrate that the first 39 amino acids of p14ARF 
are necessary and sufficient for the association with TBP-1. 
Subsequently, I determined the region of ARF necessary to obtain the 
stabilization effect exerted by TBP-1. To this purpose I transfected in 
U2OS cells, fixed amounts of the constructs expressing the different 
deletion mutants of ARF previously described, together with increasing 
amounts of TBP-1. As shown in figure 4, coexpression of wtARF with 
TBP-1 results in a significant increase of ARF levels, as expected. The 
same effect is observed also on the ARF1-39 and ARF1-65 mutants. On the 
contrary, the ARF39-132 and ARF65-132, that are unable to interact with 
TBP-1, do not accumulate following TBP-1 overexpression. These 
results strongly indicate that the interaction with TBP-1 is strictly 
required in order to obtain the stabilization of ARF intracellular levels. 
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Figure 2 The ARF39-132 is unable to interact with TBP-1. 
U2OS cells were transfected with 2 µg of the pcDNA ARF or the pcDNA ARF 39-132 
expression vector alone or together with 2 µg of pcDNA TBP-1; 15 µg of the whole 
extract were analysed with anti-ARF or anti-His antibodies (input), to reveal only 
transfected TBP-1, whereas 800 µg of the lysate were immunoprecipitated with anti-
TBP-1 or anti-ARF and revealed by anti-ARF and anti-TPB-1 antibodies. 
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Figure 3 The first 39 amino acids of ARF are necessary for the binding to TBP-1 
U2OS cells were transfected with 0.5 µg of the pcDNA TBP-1 expression plasmid 
alone or together with 0.5 µg of the 3xFlag ARF1-39, 3xFlag ARF1-65 or 3xFlag 
ARF65-132 expression vectors; lysates were analysed by anti-His or anti-Flag 
antibodies (input), immunoprecipitated with anti-TBP-1 antibody and analysed with 
anti-His and anti-Flag antibodies. 
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Figure  4 The first 39 amino acids of ARF are necessary for the stabilization 
effect exerted by TBP-1. 
Upper panel: U2OS cells were transfected with pcDN AARF or pcDNA ARF39-132 
alone or together with pcDNA TBP-1 in a 1:2 ratio; lysates were analysed with anti-
ARF, anti-His and anti-actin antibodies.  
Lower panel: U2OS cells were transfected with 0.3 µg of the 3xFlag ARF1-39, 3xFlag 
ARF1-65 or 3xFlag ARF65-132 expression  plasmids alone or with increasing amounts 
of pcDNA TBP-1; lysates were resolved by SDS-PAGE and analysed with anti-His, 
anti-Flag and anti-actin antibodies.  
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Interestingly, TBP-1 overexpression seems to exert a stronger 
stabilization effect on the ARF1-39 mutant respect to the wtARF or to the 
ARF1-65 mutant. I hypothesized that this effect could be due to the fact 
that the 1-39 peptide is less stable. To go through this point, I measured 
the ARF1-39 half life in the absence and in presence of TBP-1 
overexpression. To this aim I transfected U2OS cells with a plasmid 
encoding ARF1-39 with or without  pcDNA TBP-1 and 24 hours after 
transfection, I treated the cells with cycloheximide to inhibit protein 
synthesis. At the indicated times after exposure to the drug, cells were 
harvested and the extracts analyzed by Western Blot and probed with 
anti-His (to revel TBP-1), anti-Flag (to reveal ARF) and anti-Actina 
antibodies. As indicated in figure 5, ARF1-39 half-life is below 2 hours 
but is shifted to around 4 hours when the cells are cotransfected with 
TBP-1, confirming that the TBP-1 stabilization effect is exerted at the 
posttranslational level also on the ARF1-39 peptide as on wtARF (Pollice 
et al., 2004). I also performed a similar experiment to determine the half-
life of the ARF39-132. This mutant displays a shorter half-life respect to 
wtARF, confirming again that the 1-39 N-terminal region plays an 
important role in regulating the ARF turnover.  
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Figure  5 Evaluation of the ARF1-39 and ARF39-132 half life. 
Left panel: U2OS cells were transfected with 0.3 µg of the 3xFlag ARF1-39 
expression vector in the presence or absence of the pcDNA TBP-1 expression 
plasmid. Twenty-four hours after transfection, cells were treated with cycloheximide 
(80µg/ml) and then harvested at the indicated time points. Lysates were analysed 
with anti-Flag, anti-actin and anti-His antibodies.  
Right panel: U2OS cells were transfected with 0.3 µg of a plasmid encoding for 
pcDNA ARF or pcDNA ARF39-132. Twenty-four hours after transfection, 
cycloheximide was added and the cells were harvested at the indicated time points. 
Lysates were analysed with anti-ARF and anti-actin antibodies. 
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As there is still some disagreement as to whether the p14ARF N-terminal 
region fully maintains all the biological activity (Lohrum et al., 2000; 
Rodway et al., 2004), I wanted to get insights into the functionality of 
the ARF1-39 peptide. I examined the ability of this peptide to prevent 
MDM2-mediated degradation of p53. To this purpose I transfected an 
expression plasmid coding for MDM2 in U2OS cells (that express high 
levels of endogenous p53), alone or in combination with increasing 
amounts of the 3xFlag ARF or 3xFlag ARF1-39. As expected, p53 levels 
decrease following MDM2 overexpression, but wild-type ARF, as well 
as the ARF1-39 peptide, counteracted this effect, being able to prevent 
MDM2-mediated p53 degradation (Figure 6). These data indicate that, at 
least in the p53/MDM2 pathway, the ARF1-39 peptide retains its 
biological function. Many studies pointed to a role of the subcellular 
localization of ARF in its biological functions, although there is still a 
debate around this issue (Weber et al., 2000; Rodway et al., 2004). To 
investigate on this point I analyzed the subcellular localization of the 
ARF1-39 and ARF39-132 peptides. Interestingly, I observed that while 
ARF39-132 retains the main nucleolar localization, the ARF1-39 shows a 
more diffuse staining, suggesting that, since the ARF1-39 peptide retains 
its biological activity (see above), the nucleolar localization is not 
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essential for ARF function, at least in the MDM2/p53 pathway      
(Figure 7). 
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Figure  6 Biological function of the p14ARF1-39 N-terminal peptide. 
U2OS cells were transfected with 0.2 µg of pCMV MDM2 plasmid alone or in 
combination with increasing amounts of 3xFlag ARF or 3xFlag ARF1-39 vectors. 
Lysates were analysed with anti-p53, anti-Flag (to reveal ARF) and anti-actin 
antibodies. 
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Figure 7 The ARF1-39 peptide loses the typical ARF nucleolar localization. 
U2OS cells were transfected with GFP ARF, GFP ARF1-39 and GFP ARF39-132 and 
fixed 24 hours after transfection. Nuclei were visualized by 4-6-diamidino-2-
phenylindole (DAPI) staining.  
U2OS cells were transfected with 3xFlag ARF and 3xFlag ARF1-39, fixed 24 hours 
after transfection and immunostained with anti-Flag antibodies. Nuclei were 
visualized by DAPI staining. 
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To analyze the N-terminal 39 amino acids in more detail, I decided to 
use different mutants of ARF bearing small deletions in the first 39 
amino acids, kindly provided by Dr. Sherr. They correspond to the 
pcDNA ARFΔ2-14 and the pcDNA ARFΔ26-37. As control, I used the 
pcDNA ARFΔ82-101 plasmid. Each plasmid was transfected in U2OS cells 
alone or together with increasing amounts of pcDNA TBP-1. The protein 
extract were immunoprecipitated with anti ARF antibodies and revealed 
with anti-His and anti-ARF antibodies. Figure 8(upper panel) shows that 
similar levels of the different ARF proteins were recovered from 
transfected cell lines, but significantly less TBP-1 was coprecipitated 
from cells expressing ARF2-14 and ARF26-37 mutants. Finally, I tested 
the protein levels following TBP-1 overexpression (Figure 8 lower 
panel). The mutants that fail to interact strongly with TBP-1 do not 
increase, suggesting that efficient binding and stabilization requires an 
intact ARF N-terminal portion. 
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Figure 8 Efficient binding and stabilization requires an intact ARF N-terminal 
portion. 
Upper panel: U2OS cells were transfected with pcDNA TBP-1 alone or together with 
the ARF plasmids indicated. 48 hours after transfection protein extracts were 
prepared and immunoprecipitated with anti-ARF antibodies where indicated and 
revealed with anti-His and anti-ARF antibodies. For negative control, the 
immunoprecipitation of the same extract was performed without anti-ARF.  
Lower panel: U2OS cells were transfected with 0.3 µg of the indicated plasmids 
alone or together with increasing amounts of pcDNA TBP-1 (0.3; 0.6; 0.9 and 1.2 
µg). Cell lysates were resolved by SDS-PAGE and analysed by Western Blot with 
anti-ARF, anti-His and anti-actin antibodies.  
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p14ARF is degraded by the proteasome and TBP-1 protects it 
both in cells and in vitro. 
The mechanisms governing ARF’s turnover are not yet completely 
clarified being ARF a lysine-less and a relatively stable protein. 
Recently, it has been reported that ARF protein degradation occurs, at 
least in part, through the proteasome (Kuo et al., 2004, Rodway et al., 
2004), (for more details see Introduction). However, accumulation of 
endogenous ARF following treatment with proteasome inhibitors is 
almost undetectable in various cell lines, suggesting that may exist other 
mechanisms mediating ARF destruction. To go through this point, I 
checked ARF protein levels after treatment with proteasome and 
lysosome inhibitors. I exposed HEK293T cells (human embrional 
kidney) that present good endogenous levels of p14ARF to various 
lysosomes (Ammonium Chloride, Cloroquine and Bafylomicin) and 
proteasome (MG132 and ALLnL) inhibitors. As indicated in figure 9, 
ARF does not accumulate with any of the lysosome inhibitors used but it 
slightly increases with either MG132 or ALLnL. Furthermore, the 
ARF39-132 mutant, with a significantly shorter half-life respect to the wild 
type, clearly accumulate after treatment with proteasome inhibitors 
confirming that ARF is subjected to degradation by the proteasome.  
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Figure 9 ARF is degraded by the proteasome in mammalian cells. 
Twenty-four hours after the plating, 293T cells were treated for 6 hours with 
proteasome  (MG132 25 µM and ALLnL 50 µM) and lysosome inhibitors 
(Bafilomycin 100 nM, NH4Cl 25 µM and Cloroquine 200 µM). Lysates were 
resolved by SDS-PAGE and analysed with anti-ARF and anti-actin. 
Right panel: U2OS cells were transfected with the pcDNA ARF39-132 plasmid and, 24 
hours after transfection, treated with ALLnL or MG132. Lysates were analyzed with 
anti-ARF and anti-actin antibodies. 
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Moreover, stabilization of the ARF1-39 mutant owing to overexpression 
of TBP-1 is further increased by addition of MG132 when a 1:1 ratio 
between TBP-1 and ARF mutant is used in the transfection. However, 
when a higher amount of TBP-1 is transfected, the ARF1-39 mutant 
accumulates at higher levels that do not further increase after treatment 
with proteasome inhibitor (Figure 10). These results suggest that TBP-1, 
as well as proteasome inhibitors, protects ARF from proteasome 
degradation. 
                        
 
Figure  10 TBP-1 overexpression, as well as proteasome inhibitors MG132, 
protects ARF1-39 from degradation. 
U2OS cells were transfected with 3xFlag ARF1-39 plasmid alone or with increasing 
amount of TBP-1 vector and, 24 hours after transfection, treated with MG132 for 10 
hours. Lysates were analysed with anti-Flag, anti-His and anti-actin antibodies.  
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The proteasome plays a central role in the degradation of the majority of 
cellular proteins in eukaryotes. Recently, it is emerging an involvement 
of the proteasome also in the degradation of non-ubiquitineted proteins 
that appear to be physiologically important in higher eukaryotes (Sdek et 
al., 2005; Kong et al., 2006). In this process, the 20S proteasome subunit 
and, more recently, the REG/11S subunit seem to play a central role 
(Chen et al., 2007). Since it has been described that ARF is dynamically 
disordered in acqueous solution (Bothner et al., 2001) and largely 
unstructured in vivo, I wanted to test whether it can be subjected to 
proteasome degradation in vitro, in the absence of ubiquitination. To this 
purpose, I used in vitro translated proteins (for details see materials and 
methods). In particular I used ARF, TBP-1 and, as control, p21
waf
 since it 
has already been shown to be naturally unstructured and degraded in 
vitro by the 20S proteasome (Liu et al., 2003). The samples were 
resolved by SDS-Page and immunodetected with antibodies against 
ARF, TBP-1 and p21 (Figure 11). As it is possible to observe, ARF is 
efficiently degraded by the 20S proteasome as well as p21 and 
accumulates after treatment with the proteasome inhibitor MG132, 
whereas TBP-1 levels are unchanged. Similarly, the ARF39-132 mutant is 
degraded in vitro, in the same kind of experiments, with a faster kinetic 
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that probably reflects the shorter half life of this mutant observed in cells 
(Figure 12).  
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Figure 11 ARF is degraded in vitro by the 20S proteasome.  
In vitro translated p14ARF, p21 or TBP-1 were incubated with or without 20S 
proteasome for 1 or 3 hours at 37ºC. MG132 (50 µM) was added to the reaction 
where indicated. Samples were resolved by SDS-PAGE and immunoblotted with 
anti-ARF, anti-p21 or anti-TBP-1 antibodies. 
  
3 1 2 3 3 1 2 3
/ + + + / + + +
ARF ARF 39-132
hrs
20S proteasome
 
Figure 12 The ARF39-132 mutant is degraded in vitro by 20S proteasome. 
In vitro translated p14ARF or p14ARF39-132 were incubated with or without 20S 
proteasome for the indicated time intervals and analysed with anti-ARF antibodies. 
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As previously described, TBP-1 effects on ARF protein levels strictly 
depend on the binding between the two proteins. Thus, I wanted to 
investigate whether this protection can be exerted also in vitro, in the 
absence of an assembled 19S cap, of which TBP-1 is an integral 
component. To this purpose, in vitro translated TBP-1 was incubated 
with either in vitro translated p14ARF or p14ARF39-132 before the 
degradation assay. Strikingly, I could observe a protective effect of TBP-
1 on ARF, which is not exerted on the ARF39-132 mutant, that is unable to 
interact with TBP-1 (Figure 13). The fact that TBP-1 can exert its effect 
independently from being part of the 19S suggests that a similar 
mechanism could occur in vivo.  
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Figure 13 TBP-1 protects ARF  from in vitro proteasomal degradation. 
In vitro translated p14ARF or p14ARF39-132 were incubated with or without 20S 
proteasome. In vitro translated TBP-1 was added 30’ before the reaction, where 
indicated. Samples were resolved by SDS-PAGE and immunoblotted with anti-ARF 
and anti-TBP-1 antibodies. 
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Since it has been postulated that 19S proteasome subunits possess 
chaperone-like activities (residing in the ATPAse module) it is possible 
that, upon binding, TBP-1 causes ARF to fold becoming a poor substrate 
for proteasome destruction.  
In order to test this hypothesis, I generated a TBP-1 point mutant (for 
more details see materials and methods)  in the ATPAse domain through 
site directed mutagenesis and I tested in cells its capacity to bind and 
stabilize p14ARF. U2OS cells were transfected with the pcDNA ARF 
plasmid alone or in combination with pcDNA TBP-1 ΔGKT. At 24 
hours after transfection cellular extracts were prepared and 
immunoprecipitated with antibodies against ARF, resolved by SDS-
Page, blotted and incubated with anti Xpress, to reveal transfected TBP-
1, and anti-ARF antibodies. Interestingly, as shown in figure 14, this 
mutant is able to bind to ARF. However, transfection of  U2OS with 
increasing amounts of TBP-1 ΔGKT and a fixed amounts of p14ARF do 
not cause a significant increase in ARF protein levels unlike the effect 
observed with wtTBP-1 (Figure15). These experiments suggest that 
chaperone activity of TBP-1 could be required for the stabilization 
effect. 
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Figure 14 TBP-1 ΔGKT retains the binding to ARF. 
U2OS cells were transfected with 1 µg of the pcDNA TBP-1 and pcDNA TBP-1 
ΔGKT vectors alone or together with 1 µg of the ARF plasmids. Twenty four hours 
after transfection protein extracts were immunoprecipitated with anti-ARF antibodies 
where indicated and revealed with anti-Xpress and anti-ARF antibodies. For negative 
control, the immunoprecipitation of the same extracts was performed without anti-
ARF. 
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Figure 15 TBP-1 ΔGKT is unable to efficiently increase ARF intracellular 
levels. 
U2OS cells were transfected with 0.2 µg of the pcDNA ARF plasmid alone or in 
combination with increasing amounts of pcDNA TBP-1. Cell lysates were resolved 
by SDS-PAGE and analyzed by Western Blot with anti-ARF, anti-Xpress and anti-
actin antibodies. 
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MDM2 is able to regulate p14ARF intracellular levels.  
As previously described, some authors (Kuo et al., 2004) reported that 
ARF could be subjected to N-terminal ubiquitination, a process that 
requires a free N-terminus and that seems strictly dependent on the first 
2–3 amino acids of the protein (see Introduction). Interestingly, it has 
been shown that TBP-1, as part of the regulatory subunit of the 
proteasome, is involved in the recognition of the polyubiquitin chains 
(Lam et al., 2002). As the binding of ARF to TBP-1 requires the N-
terminus of the protein, I reasoned that it could occur via the 
polyubiquitin chain. Therefore, I could expect that changes of the ARF 
N-terminal amino acids would impair the stabilization effect. However, I 
have proven that TBP-1 overexpression determines stabilization of ARF 
proteins independently from the extreme N-terminal sequence (Figure 16 
and figure 4 previously shown). Overall, it appears that putative N-
terminal ubiquitination does not significantly influence TBP-1 mediated 
stabilization.  
On the other hand, other authors (Rodway et al., 2004) do not observe 
ubiquitination of ARF but claim the importance of the MDM2 ubiquitin-
ligase in the regulation of ARF intracellular levels, although the 
mechanism through which it occurs is not yet defined. It has also been 
reported that MDM2 could be involved in the ubiquitin-independent 
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degradation of some proteins, such as p21 (Jin et al., 2003) an pRb (Sdek 
et al., 2005). Zhang and coworkers (2004) provided evidences that 
MDM2 promotes p21 degradation directly binding to it and facilitating 
its association with the C8 subunit of the 20S proteasome. Sdek and 
coworkers (2005) described a similar behaviour for pRb. They found that 
MDM2 promotes Rb degradation in a proteasome-dependent, ubiquitin-
independent manner in analogy to p21. 
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Figure 16 TBP-1 stabilizes ARF independently from its N-terminal sequence. 
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Since ARF is degraded in vitro by the 20S proteasome (Pollice et al., 
2007) and is prevalently unstructured I decided to perform experiments 
to test the potential involvement of MDM2 in the regulation of ARF 
turnover. I thus transfected U2OS cells with increasing amounts of a 
vector encoding for wtMDM2 or for two deletion mutants of MDM2, 
MDM21-441, lacking the ring finger (the portion of the protein involved in 
the ubiquitination process) and MDM2150-230 (a mutant lacking the NES 
and NLS sequences, causing relocalization of MDM2 in the cytoplasm) 
together with a fixed amounts of p14ARF. Western blot of whole 
extracts and specific immunodetection with anti-MDM2 antibodies and 
anti-ARF antibodies show that the overexpression of MDM2, as well as 
of its mutant forms, cause a remarkable decrease of p14ARF protein 
levels (Figure 17). Interestingly, this effect occurs also on endogenous 
ARF protein levels in H1299 cells (Figure 18). In order to verify if ARF 
could be degraded by the 20S proteasome through the binding to C8 in 
analogy with p21 and Rb, I performed experiments of GST pull-down. 
Unfortunately the results were not unequivocal. 
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Figure 17 Effect of wt MDM2, MDM21-441 and MDM2150-230 on ARF. 
U2OS cells were transfected with 0.2 µg of the pcDNA ARF plasmid alone or in 
combination with increasing amounts of the plasmids indicated. Cell lysates were 
resolved by SDS-PAGE and analysed by Western Blot with anti-MDM2, anti-ARF 
and anti-actin antibodies. 
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Figure 18 Effect of wtMDM2 on endogenous ARF in H1299. 
H1299 cells were transfected with increasing amounts of wtMDM2 plasmid. Whole 
cell extract was run on a SDS-Page and immunorevealed by Western Blot with anti-
MDM2, anti-ARF and anti-actin antibodies. 
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To determine which portion of ARF was required for the degradation 
effect exerted by MDM2, I transfected U2OS cells with plasmids coding 
for different deletion mutants of ARF together with increasing amounts 
of wtMDM2. They corresponded to ARF2-14 (lacking a nucleolar 
localization signal in exon 1), ARF82-101 (lacking a localization signal 
present in the exon 2), ARFΔ2-14/Δ82-101, ARF1-65 (that retains only exon 1 
and ARF65-132 (that retains exon 2). Interestingly, protein levels of all the 
ARF mutants, except that of the ARF65-132, were reduced following 
MDM2 overexpression suggesting that the first 65 amino acids of ARF 
are important for the degradation effect (Figure 19).  
I then evaluated the capability of the different ARF mutants to bind to 
MDM2. To this purpose, whole cell extract of U2OS cells transfected 
with ARFΔ2-14/Δ82-101 and, as control, with the wtARF plasmid, alone or in 
presence of MDM2, were subjected to immunoprecipitation with anti-
ARF antibody, run on a SDS-PAGE, blotted and immunodetected with 
anti-ARF and anti-MDM2 antibodies. Figure 20 shows that the ARFΔ2-
14/Δ82-101 is able to bind to MDM2. Similarly, the ARF1-65 mutant is able to 
bind to MDM2 unlike the ARF65-132.  
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Figure 19 The first 65 amino acids of ARF are important in order that MDM2 
exerted its degradation effect on ARF. 
(Upper) U2OS cells were transfected with 0.3 µg of the ARF mutants alone or in 
combination with increasing amounts of wtMDM2 (0.6 and 0.9µg).Cell lysates were 
resolved by SDS-PAGE and analysed by Western Blot with anti-MDM2, anti-ARF 
and anti-actin antibodies. 
(Lower) U2OS cells were cotransfected with 0.3 µg of the pCMV ARF Flag1-65 and 
pCMV ARF Flag65-132 plasmids and increasing amounts (0.3; 0.6 and 0.9 µg) of 
MDM2 expression vector. Twenty four hours after transfection cell extracts were 
analyzed by Western blot and immunorevealed with anti MDM2, anti Flag and anti 
actin antibodies.  
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Figure 20 ARF Flag65-132 that is not degraded by MDM2 loses its capability to 
bind to it. 
(Upper) U2OS cells were transfected with 1 µg of pcDNA ARF and pcDNA ARFΔ2-
14/Δ82-101 vectors alone or together with the MDM2 plasmids. Twenty four hours after 
transfection protein extracts were immunoprecipitated with anti-ARF antibodies 
where indicated and revealed with anti-MDM2 and anti-ARF antibodies. For 
negative control, the immunoprecipitation of the same extracts was performed 
without anti-ARF. 
(Lower) U2OS cells were transfected with 0.5 µg of pCMV ARF Flag1-65 and pCMV 
ARF Flag65-132 vectors alone or in combination with the MDM2 plasmids. Twenty 
four hours after transfection cell extracts were immunoprecipitated with anti-MDM2 
antibodies where indicated and revealed with anti-MDM2 and anti-ARF antibodies. 
For negative control, the immunoprecipitation of the same extracts was performed 
without anti-MDM2. 
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Consistently, the MDM2 mutants that are able to degrade ARF (see 
above) bind to it (Figure 21). Overall, these results led to the hypothesis 
that the interaction between ARF and MDM2 is crucial for ARF 
degradation following MDM2 overexpression.  
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Figure 21 All the MDM2 mutants bind to ARF. 
U2OS cells were transfected with 1 µg of the pcDNA ARF expression plasmid alone 
or together with 1µg of the wtMDM2, MDM21-441 and MDM2150-230 expression 
vectors; lysates were analysed by anti-MDM2, or anti-ARF antibodies (input), 
immunoprecipitated with anti-ARF antibody and immunocomplex were analyzed 
with anti-MDM2 and anti-ARF antibodies. 
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Interestingly, I observed a decrease of ARF protein levels, in response to 
MDM2 overexpression, also in p53-/- MDM2-/- context (Mouse Embryo 
Fibroblasts), indicating that the observed effect, is p53 independent 
(Figure 22). 
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Figure 22 MDM2-mediated ARF degradation occurs in p53 independent 
manner. 
Mouse Embryo Fibroblasts (p53-/- MDM2-/-) were transfected with 0.1 µg of 
pcDNA ARF alone or together with increasing amounts of MDM2 expression vector. 
At 24 hours after transfection cell extracts were analyzed by Western blot and  
immunodetection with anti MDM2, anti ARF antibodies. Anti actin antibody was 
used as loading control. 
 
Results 
71 
ROLE OF TBP-1 IN THE CONTROL OF CELL GROWTH. 
 
During the last ten years many reports highlighted a very interesting 
aspect regarding the potential role of TBP-1 in the control of cell 
proliferation, supported by various evidences. Among these, our 
observation that TBP-1 increases the p14ARF oncosuppressor 
intracellular levels well fits with the proposed antioncogenic role of 
TBP-1 (Pollice et al., 2004; 2007). Interestingly, the potential 
oncosuppressive role of TBP-1 appears not to be restricted to the effect 
on ARF as we and others (Park et al., 1999; Corn et al., 2003) have 
demonstrated that TBP-1 overexpression can inhibit cell proliferation in 
various cellular contexts also independently by the presence of ARF. 
These observations not only further underlie the potential 
antiproliferative role of TBP-1 but suggest that it can exert a more 
general ARF-independent role in the control of cell proliferation and 
raise the question of what kind of cellular signals modulate TBP-1 
expression.   
In our laboratory the potential role of TBP-1 as a regulator of cell 
proliferation has been addressed. To this aim primary human fibroblasts 
immortalized cell derivatives, constitutively expressing an shRNA 
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specifically designed to silence TBP-1 expression, were used. The 
obtained clones show the following features: 
 The clones express different levels of TBP-1 whereas the protein 
levels of other proteasome subunits, as well as the proteasome 
activity measured by cleavage of synthetic substrates, are 
unaffected by the silencing of TBP-1.  
 the clones display a higher proliferation rate respect to the control 
and are able to sustain growth in the absence of serum. 
 the clones display an increase of the S-phase and are more 
resistant to serum starvation induced apoptosis. 
Overall, these data indicate that high TBP-1 levels contributes to control 
cell proliferation.  
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TBP-1 inhibits PKB/Akt activation. 
The observations that clones in which TBP-1 expression is silenced 
present a higher proliferation rate respect to the control and can sustain 
growth in the absence of serum, raise the question of which are the 
potential intracellular pathways involved.  
To go trough this point, I wondered whether the extent of TBP-1 
expression may regulate the activation status and/or the levels of 
expression of proteins involved in the control of cell cycle progression. 
To this aim, by western blot, I evaluated the levels of phospho-Akt, a 
protein kinase controlling the balance between cell survival and 
apoptosis, in three silenced clones (T1, T10C, and T10E). As shown in 
figure 23, the level of pAkt seems to be inversely correlated to the extent 
of silencing, being lower in the parental T11HT and higher in the T1 
clone. Furthermore, a corresponding reduction in the p21
Waf
 and in the 
phospho-cyclinD1 levels appears to be consistent with the observed 
higher proliferation rate and with the Akt enhanced activation. 
To further confirm that depletion of TBP-1expression results in the 
increase of activation of PKB/Akt, I treated the T1 clone and parental 
cells with Wortmannin and LY294002, two different inhibitors of the 
upstream Akt regulator PI3K. 
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Figure 23 TBP-1 silenced clones show higher levels of activated PKB/Akt. 
Wild-type T11hT, T1, T10E and T10C cells were plated in 100 mm dishes. 48 hours 
upon plating cellular extracts were prepared, resolved by SDS-PAGE and 
immunoblotted with the antibodies indicate.  
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As it is possible to observe in figure 24 the steady state level of pAkt in 
the T1 clone is around twice that present in the parental cells. 
Furthermore, the drug concentration necessary to inhibit pAkt level is 
almost the double as compared to that needed to inhibit pAkt level in the 
parental cells. 
Since TBP-1 silencing causes an increase of the steady state levels of 
pAkt, I supposed that TBP-1 could control the extent of PKB/Akt 
activation. Consequently, I would expect that high levels of TBP-1 may 
exert a negative control either directly or indirectly on the activation of 
Akt. To this purpose I performed overexpression experiments of TBP-1 
in U2OS cells and 24 hours upon transfection cell extracts were analyzed 
with antibodies either against TBP-1 or pAkt. Unfortunately the results 
were not unequivocal (data not shown). Therefore, I decided to evaluate 
the extent of PKB/Akt activation following insulin stimulation, a well 
known inducer of PKB/Akt. As shown in Figure 25, when TBP-1 is 
overexpressed, insulin stimulation causes a reduced activation of Akt, 
confirming that TBP-1 may contribute to pAkt regulation. Taken 
together these data suggest that TBP-1 may exert an antiproliferative 
effect by negatively regulating the Akt pathway. 
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Figure 24 TBP-1 downregulation in the T1clone renders the cells more resistant 
to Wortmannin and LY294002 inhibitors. 
T11hT cell line and T1 clone were plated in 35 mm dishes. Twenty four hours after 
the plating, the cells were treated with Wortmannin for 1 hour and LY2940002 for 15 
minutes. Then, the cells were harvested and analyzed by Western Blot with anti 
pAkt, anti PKB/Akt and anti Actin antibodies. 
 
insulin - - +      +     +       +
TBP-1
pAkt
actin
PKB/Akt
Transfected
Endogenous
c
TBP-1
 
Figure 25 Overexpression of TBP-1 downregulates pAkt levels. 
U2OS cells were transfected with 0.2 and 0.5 µg of the pcDNA TBP-1 expression  
vector. At 24 hours after transfection, cells were starved for 4 hours and then treated 
with 10 ng/ml insulin for 10 minutes. Extracts were analyzed by Western blot and  
immunorevealed with anti TBP-1, anti pAkt, anti PKB/Akt and anti Actin antibodies. 
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TBP-1 is a downstream target of Akt activation. 
Since I have demonstrated that TBP-1 can inhibit the activation of pAkt 
following insulin stimulation I wondered if Akt could exert a down 
regulation of TBP-1, as well. U2OS osteosarcoma cells were starved for 
four hours and then stimulated by insulin addition at the concentration of 
10 ng/ml for the indicated time periods. Protein lysates were prepared 
and analyzed by western blots with anti-TBP-1 and anti pAkt antibodies. 
Strikingly, insulin treatment results in a rapid drop of TBP-1 intracellular 
levels: TBP-1 levels are reduced of around two times in 5 minutes and 
remain low up to 40 minutes with a kinetic that mirrors that of activation 
of Akt. This effect results specific to TBP-1 as other proteasome 
subunits protein levels (PSMC5 and C8) remain unchanged following 
insulin treatment (Figure 26). Consistently, treating cells with the PI3K 
inhibitors Wortmannin and LY294002, I observed a slight but 
reproducible increase in TBP-1 endogenous levels (Figure 27).  
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Figure 26 TBP-1 levels decrease following treatment with insulin. 
U2OS cells were starved for 4 hours and then treated with 10 ng/ml of insulin for the 
time indicated. Cellular lysates were analyzed by Western Blot and revealed with 
anti pAkt, anti TBP-1, anti PSMC5 and anti C8 antibodies. Anti actin was used as 
loading control. 
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Figure 27 PI3K inhibitors upregulate TBP-1 levels. 
U2OS cells  were treated with 200 nM of Wortmannin and 50M of LY294002 for 
the time indicated. Whole extracts were analyzed by Western Blot and 
immunorevealed with anti pAkt, anti TBP-1, anti Actin, anti PSMC5 and anti C8 
antibodies. 
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Overall these data indicate that insulin down regulation of TBP-1 levels 
is mediated by the PI3K/Akt pathway. Further, the rapidity of such 
decrease, strongly suggests that insulin likely acts by inducing a drastic 
reduction in TBP-1 protein stability rather than by interfering with its 
biosynthesis. On the other hand, the low efficiency of PI3K inhibitors in 
increasing the TBP-1 steady state levels well fits with the hypothesis of a 
further small increase in its stability. 
To further confirm the importance of the PI3K/Akt pathway in 
controlling TBP-1 levels I performed overexpression experiments using 
the Constitutively Active mutant of Akt (CA Akt), which is brought to 
the plasma membrane independently from the PI3K activity. U2OS cells 
were transfected with increasing amount of CA Akt and then analyzed 
by Western Blot with antibodies against TBP-1 and pAkt. As indicated 
in figure 28, the overexpression of CA Akt causes a remarkable 
reduction in TBP-1 endogenous levels. Furthermore, a corresponding 
increase in the pGSK3β levels, a direct downstream target of Akt, 
resulted consistent with the observed Akt activation. Interestingly, the 
other proteasome subunits analyzed do not change following Akt CA 
overexpression suggesting that this effect is specific to TBP-1. 
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Figure 28 Effect of CA Akt mutant on TBP-1. 
U2OS cells were transfected with increasing amounts of the CA Akt plasmid (0.2; 
0.5; 1 g). Twenty four hours after transfection cells were harvested, run on a SDS-
PAGE and immunoblotted with the antibodies indicated in figure. 
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Regulation of  TBP-1 intracellular levels by Akt occurs through 
MDM2. 
The involvement of PI3K/Akt pathway in the regulation of MDM2 
levels has been largely demonstrated. When activated, Akt is able to 
phosphorylate a vast number of proteins, MDM2 among them. Although 
there are still disagreements around which are the target residues 
important for MDM2 phosphorylation (Mayo et al., 2001; Ogawara et 
al., 2002; Feng et al., 2004) seems quite clear that MDM2 
phosphorylation by Akt results in its stabilization with consequent 
protection from proteasomal degradation. Since TBP-1 levels are 
regulated by Akt I wondered if MDM2 could be a  mediator in this 
pathway. To test this hypothesis I used the Akt inhibitor Wortmannin on 
U20S cells in which the MDM2 expression has been silenced with 
specific siRNA. As expected, treatment of cells with the PI3K inhibitor 
results in an increase of TBP-1 levels  (figure 29 left) that is abolished 
when MDM2 levels are reduced by siRNA(figure 29 right), suggesting 
that MDM2 could be a mediator of the TBP-1 increase following Akt 
downregulation. 
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Figure 29 Treatment of cells with Wortmannin causes TBP-1 accumulation only 
in the presence of high levels of MDM2. 
U2OS cells were transfected with 10 nM MDM2 siRNA or firefly luciferase siRNA. 
48 hours after transfection cells were treated with Wortmannin for 2 and 4 hours, cell 
extracts were prepared, resolved by SDS Page and immunorevealed  with the 
antibodies indicated in figure. 
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To keep more insights into the regulation of TBP-1 levels by MDM2, I 
tested if TBP-1 is a direct target of MDM2. To this purpose, I performed 
coimmunoprecipitation experiments to check the binding between the 
two proteins. U2OS cells were immunoprecipitated with anti-MDM2 
antibody and revealed with either anti-MDM2 or anti-TBP-1 antibodies. 
As showed in figure 30 TBP-1 results a binding partner of MDM2. 
Interestingly, in U2OS cells, I observed that MDM2 overexpression 
causes a strong decrease in TBP-1 levels, both endogenous and 
transfected (Figure 31). 
 
 
 
 
 
Figure  30 TBP-1 interacts with MDM2. 
U2OS cells were transfected with 1 µg of the pCMV MDM2 expression plasmid 
where indicated. Lysates were analysed by anti-MDM2 or anti-TBP-1 antibodies 
(input), immunoprecipitated with anti-MDM2 antibody and revealed with anti-
MDM2 and anti-TBP-1 antibodies. 
MDM2
+            - - +            
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+                       +
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Figure 31 MDM2 overexpression causes decrease of TBP-1 levels, both 
endogenous and transfected. 
U2OS cells were transfected with increasing amounts of the MDM2 plasmid  to 
evaluate the effect on the endogenous TBP-1 levels and cotransfected with a fixed 
amount of the TBP-1 plasmid and increasing amounts of the MDM2 vector. Cell 
lysates were analyzed by Western Blot with anti MDM2, anti TBP-1 and anti actin 
antibodies. 
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Importantly, this effect  does not require the ubiquitine ligase activity of 
MDM2, since the MDM21-441 (lacking the ring finger) is still able to 
degrade TBP-1. Conversely, the MDM2Δ150-230 mutant, that displays a 
cytoplasmic localization, is unable to degrade TBP-1 suggesting that the 
observed effect requires the translocation of MDM2 in the nucleus 
(Figure 32), although further experiment are needed to elucidate this 
point. 
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Figure 32 Effect of the MDM2 mutants on TBP-1. 
U2OS cells were transfected with 0.1 µg of the TBP-1 plasmid alone or together with 
increasing amounts of the MDM2 plasmids indicated. Cellular extracts were resolved 
by SDS PAGE and analyzed by Western Blot with anti MDM2 and anti Xpress (to 
reveal TBP-1) antibodies. Actin was checked as loading control. 
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Finally, to gain more insights into the mechanism responsible of the 
TBP-1 degradation, I performed the same kind of experiments also in 
(p53-/-mdm2-/-) Mouse Embryo Fibroblasts. MEFs cells were 
transfected with a fixed amount of TBP-1 and increasing amounts of the 
MDM2 vector. Western blot of whole extracts and specific 
immunodetection with anti-MDM2 antibodies and anti-Xpress 
antibodies show that also in this cellular context, MDM2 is able to 
degrade efficiently TBP-1 suggesting that this effect is p53 independent   
(Figure 33). 
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Figure 33 MDM2 downregulates TBP-1 in a p53 independent manner. 
Mouse Embryo Fibroblasts (p53-/- MDM2-/-) were transfected with 0.1 µg of the 
pcDNA TBP-1 alone or together with increasing amounts of the MDM2 expression 
vector. At 24 hours after transfection cell extracts were analyzed by Western blot and  
immunodetection with anti MDM2, anti Xpress (to reveal TBP-1) and anti Actin 
antibodies. 
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DISCUSSION 
 
TBP-1 belongs to the AAA-ATPases gene family (ATPAses Associated 
to a variety of cellular Activities) and, as well as other members of this 
family, is a component of the 19S subunit of the proteasome. 
Interestingly, during the last years, 19S proteasome subunits and TBP-1 
itself turned out to be involved also in cellular events that do not require 
proteolysis, such as the regulation of transcription (Gonzalez et al., 2002; 
Ferdous et al., 2002; Sulahian et al., 2006), the involvement in N.E.R. 
(Nucleotide Excision Repair) (Russell et al., 1999) and in the mitotic 
process (Chen et al., 1997). 
Furthermore, several evidences support a potential tumour-suppressive 
role of TBP-1: its expression was found to be elevated following 
inhibition of the oncogenic phenotype of erb-B transformed cells 
suggesting that its activation could be necessary to counteract oncogenic 
signals (Park et al., 1999). Consistently, forced expression of TBP-1 in 
different human tumour cells diminished cell proliferation, reduced the 
ability of the parental cell line to form colonies in vitro and strongly 
inhibited the transforming efficiency in the athymic mice (Park et al., 
1999). Moreover, TBP-1 has been shown to bind to the tumour 
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suppressor VHL (Von Hippel Landau) gene product (Corn et al., 2003) 
contributing to its E3-ubiquitin ligase function toward the Hif1 factor, 
thus acting as a bona fide tumour suppressor.  
Our observation that TBP-1 interacts with and stabilizes the p14ARF 
oncosuppressor delaying its turnover, well fits with its proposed 
antioncogenic role (Pollice et al., 2004). Interestingly, the fact that TBP-
1 overexpression diminished cellular proliferation also in ARF minus 
contexts (Pollice et al, 2004) suggests that its potential oncosuppressive 
role is not restrict to the effect on ARF but can exert a more general 
ARF-independent role in the control of cell proliferation. 
ARF is among the most relevant tumour suppressors in mammalian cells, 
sensing hyperproliferative stimuli and acting to restrict cell proliferation 
through both p53-dependent and independent pathways (Lowe et al., 
2003). The discovery of multiple ARF interactors and the observation 
that, aside oncogenic stimuli, also viral, genotoxic, hypoxic and 
oxidative stresses activate an ARF dependent response, suggest that ARF 
could exert a wider role to protect the cell (Fatyol et al., 2001; Menendez 
et al., 2003; Garcia et al., 2006). 
It is becoming clear that the ARF response is quite complex and is likely 
accomplished by the interaction with a multitude of cellular partners that 
makes difficult the formulation of a unique model that could depict the 
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ARF role in the cell. On the other side, the regulation of ARF 
intracellular levels itself is not yet completely clear and the mechanisms 
regulating its turnover appear still controversial. Given its strong ability 
to block both growth and proliferation, cells must develop mechanisms 
that promptly reduce ARF protein levels when its activity is no more 
required. ARF is a relatively stable protein, although prevalently 
unstructured and largely disordered in solution (Bothner et al., 2001). 
For long time it has been thought that it could not be degraded by the 
proteasome since its sequence lacks lysine residues (the mouse protein 
presenting only one lysine residue) that can allow ubiquitination in a 
canonical way. Recently, we and others (Kuo et al., 2004, Pollice et al., 
2004, 2007) demonstrated that ARF is degraded, at least in part, by the 
proteasome, although the mechanisms governing its delivery into the 
proteasome still remain to be completely clarified. Furthermore, it has 
been reported that ARF can be subjected to N-terminal ubiquitination, a 
process independent from p53 and MDM2 (Kuo et al., 2004) whose 
physiological role is still elusive (see Introduction). 
It has to be noted that, although most cellular proteins that are directed to 
the proteasome are previously ubiquitinated, a growing body of evidence 
underline the existence of proteasome-dependent but ATP and ubiquitin-
independent mechanisms of degradation (ornithine decarboxylase, the 
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Cdk inhibitor p21, -synuclein, Hif, members of the Rb family of 
tumour suppressors, p53 and p73 (Sdek et al., 2005; Kong et al., 2006). 
In many cases, if a protein can be delivered to the proteasome in a 
denatured or partially unfolded state, ubiquitination should not be 
required for its degradation. In fact, p21 and -synuclein that are 
considered “naturally unstructured” proteins can be degraded in vitro by 
the proteasome, in the absence of ubiquitination (Liu et al., 2003). 
Accordingly to its native unstructured nature, ARF can be degraded in 
vitro by the 20S proteasome, in ATP and ubiquitin-independent manner 
(Pollice et al., 2007).  
However, a very recent report give a different explanation of the 
ubiquitin-independent and ATP-independent degradation of important 
cell-cycle regulators like ARF, p21Cip/WAF1 and p16INK4a. In this 
process there is the direct involvement of the REG proteasome, a 
regulative subunit of the proteasome that is alternative to the 19S with 
yet uncovered functions. (Chen et al., 2007). It has been proposed that 
the REG pathway is specialized for the proteasomal degradation of 
small unstructured proteins since p19ARF, p21, and p16 are all 
unstructured when not associated with specific binding partners (such as 
cyclins and Cdks, for p21 and p16, and nucleophosmin in the case of 
p19ARF).  
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Strikingly, my data show that TBP-1 is able to counteract the 
degradation of ARF by the 20S proteasome in vitro, independently from 
the presence of an assembled 19S particle, highlighting that the TBP-1 
protective effect on ARF is proteasome-independent. On the other hand, 
we have already demonstrated that a similar effect occurs also in vivo, 
since TBP-1 overexpression in various cell lines delays ARF turnover 
(Pollice et al 2004). Furthermore, I have demonstrated that silencing of 
TBP-1 expression causes a concomitant reduction of ARF intracellular 
protein levels, strongly suggesting that basal TBP-1 levels controls basal 
ARF levels. Interestingly, a point mutation in the ATPAse domain of 
TBP-1 that destroys its chaperone-like activity, impairs TBP-1’s capacity 
to stabilize ARF, leading us to postulate the hypothesis that, upon 
binding, TBP-1 could cause ARF to fold, rendering it a poor substrate 
for proteasome destruction.  
Thus, the discovery that p14ARF can directly interact with regulative 
components of the proteasome multi-protein complex, such as TBP-1 of 
the 19S subunit (Pollice et al., 2004, 2007) and REG of the 11S lid 
(Chen et al., 2007) has offered a new key to interpret the mechanisms 
through which ARF is regulated and regulates cell growth and 
proliferation. It is possible that alternative binding of ARF to different 
proteasome subunits, TBP-1 or REG could dictate its fate, mediating 
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either its stabilization or its degradation (Figure 1). It would be of great 
interest to investigate on the hypothesis of a direct competition between 
REG and TBP-1 for the binding to ARF and to explore the stimuli and 
molecular pathways involved.  
Overall my data on ARF result relevant in the comprehension of the 
regulation of its turnover. Furthermore, it is interesting to underline that 
TBP-1 is excluded from the nucleolus and binds to ARF mainly in the 
nuclear compartment (Pollice et al., 2007), where probably determines 
its folding, that is necessary to ARF for its biological function. A 
possibility still to be explored is that the interaction between ARF and 
TBP-1 is important not only to control ARF levels but could mediate the 
drag of ARF partners into the proteasome cavity. The reported 
observations that both TBP-1and ARF exert a negative effect on 
Hif1Fatyol et al., 2001; Corn et al., 2003) seem to support the idea 
that a synergy of action between ARF and the proteasome could occur.  
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Figure 1  A model for the regulation of ARF turnover. 
ARF can be degraded by the proteasome through ubiquitin independent (by 20S or 
20S/REG complex) or dependent (by 26S complex) mechanisms. Binding to 19S 
subunit TBP-1 protects ARF from degradation both in vitro and in cells.  
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Other sets of data accumulated in the laboratory and by myself pointed 
to a very interesting ARF-independent tumour suppressive role of TBP-
1. In fact human fibroblasts immortalized cell clones that constitutively 
express an shRNA designed to silence TBP-1 expression proliferate at 
higher rate respect to the control also in condition of serum deprivation, 
display an increase of the S-phase of the cell cycle and are more resistant 
to serum starvation induced apoptosis. TBP-1 silenced clones exhibit 
higher levels of activated pAkt, a protein kinase controlling the balance 
between cell survival and apoptosis, leading to the hypothesis that TBP-1 
could exert a down-modulation of activated Akt levels and activity. 
Consistently, transient overexpression of TBP-1 causes a reduced 
activation of pAkt following insulin stimulation. 
Moreover, my data demonstrate that TBP-1 is likely a downstream target 
of Akt activation. Acute insulin stimulation of U2OS osteasarcoma cell 
line causes a rapid drop in TBP-1 intracellular levels. Conversely, the 
inhibition of the PI3K/Akt pathway by making use of specific drugs 
(Wortmannin and LY) determine a reproducible increase of TBP-1 
intracellular levels. Importantly, this effect is specific to TBP-1 as other 
proteasome subunits protein levels (PSMC5 and C8) remain unchanged. 
Interestingly, it has been described that another AAA-ATPase 
component of the 19S proteasome (S4/Rpt2 ATPase ) also respond to 
Discussion 
95 
growth factor stimulation (in this case by heregulin 1) but with an 
opposite effect, i.e., an increase of its intracellular levels (Barnes et al., 
2005), strongly suggesting that the effect seen on TBP-1 is specific.  
Taken together, these data demonstrate that TBP-1 intracellular levels 
are critical to control cell duplication and are tightly regulated by a 
double-negative feedback loop that is mediated by the activation of the 
PKB/Akt kinase that thus seems to act as a sensor that modulate the 
TBP-1 levels in actively duplicating cells. As I did not observe a direct 
binding between TBP-1 and Akt, I supposed that TBP-1 is an indirect 
target of Akt activation. 
Interestingly, I accumulated preliminary data suggesting that MDM2 
could be a mediator of the PI3K/Akt signalling on TBP-1. In fact MDM2 
is among the main direct targets of PKB/Akt activation (Mayo et al., 
2001, Ogawara et al., 2002, Feng et al., 2004), and in other sets of 
experiments I demonstrated that it is a partner of TBP-1. Furthermore, 
MDM2 overexpression can cause a reduction of  both endogenous and 
transfected TBP-1 intracellular levels indicating that TBP-1 is indeed a 
target of MDM2. Strikingly, blocking the PI3K activation by the 
addition of Wortmannin to cells previously transfected with a siRNA 
designed to silence MDM2 expression, prevents the accumulation of 
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TBP-1, strongly suggesting the involvement of MDM2 in the “PI3K/Akt 
–TBP-1 axis”.  
It is interesting to note that we and others (Rodway et al., 2004) have 
observed an involvement of MDM2 also in the regulation of ARF 
protein levels. In fact MDM2 overexpression can cause a significant and 
reproducible decrease of both endogenous and transfected ARF 
intracellular levels. Interestingly, by using a mutant of MDM2 that lack 
the RING Finger domain, I demonstrated that the ubiquitin ligase 
activity is not required for the MDM2-induced degradation of both ARF 
and TBP-1. However, these results are somehow not new since it has 
already been described that proteins like p21 and pRb (Jin et al., 2003; 
Sdek et al., 2005) can be directed to proteasome-mediated degradation 
by MDM2 without preventive ubiquitination. The molecular mechanism 
through which this occurs is far to be comprised.  
These observations lead to the suggestion of a unique model of action of 
MDM2 toward targets that can be degraded without being ubiquitinated. 
However, the use of an MDM2 mutant that lacks both NES and NLS 
sequences (the MDM2150-230) and displays only a cytoplasmic 
localization, pointed out that the existence of a unique model of action of 
MDM2 both on ARF and TBP-1 cannot be assumed. In fact, the 
MDM2150-230 mutant is capable to degrade ARF, while it is not respect 
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to TBP-1. To unravel this mechanism represents an interesting subject to 
study. In any case, aside the mechanisms that have still to be clarified, 
the MDM2 action on ARF underlies the existence of a negative feedback 
loop in which ARF regulates and is regulated by MDM2 and viceversa. 
On the other hand, the same could be true for the MDM2 effect on TBP-
1, in which the MDM2 phosphorylation/activation, following insulin 
stimulation through PI3K/Akt signalling causes MDM2 to translocate in 
the nuclear compartment (Mayo et al., 2001, Ogawara et al., 2002) 
where it could act dowregulating TBP-1 levels; in turn, TBP-1 can 
counteract PKB/Akt activation that is likely reflected in a reduced 
activation of MDM2. How TBP-1 prevents PKB/Akt activation is, up to 
now, completely unknown. However, given the TBP-1 capability to 
stabilize p14ARF, one of the most important human oncosuppressors, a 
possibility to explore is that it could exert a more general role in the cell 
through the stabilization of other oncosuppressors, like, for example, 
PTEN, that is among the most important negative regulator of the PI3K 
activation (Hirsch et al., 2007; Sale et al., 2008),  
In conclusion my results suggest that TBP-1 can exert antioncogenic 
properties through different molecular mechanisms still to be explored. 
Further studies are needed for the comprehension of the mechanisms 
through which TBP-1 is regulated and regulated cell proliferation. 
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MATERIALS AND METHODS  
 
Plasmids  
 
pcDNA ARF39-132 was obtained from NarI/XbaI cut of pcDNA ARF, fill 
in at the NarI site and ligated into the pcDNA3.1His (Invitrogen) cut 
with EcoRV/XbaI.  
pcDNA ARF1-39 was obtained from EcoRI/NarI cut of pcDNA ARF, fill 
in of the NarI site, and cloning in pcDNA3c.1 EcoRI/EcoRV digested.  
3xFlag ARF1-39 was obtained by PCR amplification using the primers 
ARFup (AAGAATTCAATGGTGCGCAGG) and ARFdown 
(AAAAGATCTCCCTGGCGCTGCCCA) and subsequent cloning in 
p3xFlagCMV10 cut EcoRI/BglII.  
pEGFP ARF1-39 and pEGFP ARF39-132 were obtained from EcoRI/XbaI 
cut of respectively, pcDNAARF1-39 and pcDNA ARF39-132 and 
subsequent cloning in EcoRI/XbaI of pEGFPc2. 
pCMV3xFlag ARF, pCMV3xFlag ARF1-65 and pCMV3xFlag ARF65-132 
were kindly provided by prof. Majello. 
pcDNA ARF2-14, pcDNA ARF26-37, pcDNA ARF82-101 and 
pcDNAARF2-14/82-101 plasmids were kindly provided by CJ Sherr. 
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pcDNA TBP-1GKT deletion mutant was obtained using Quick Change 
Site Direct Mutagenesis (Stratagene) following the manufacturer’s 
instruction. Briefly, pcDNA TBP-1 plasmid (with target site for 
mutation) was denatured. After the annealing of the mutagenic primers 
(ATPf 5’-TGGGCCCCCAGGGACGCTCCTGGCCCGGGCCTG-3’, 
ATPr 5’-CAGGCCCGGGCCAGGAGCGTCCCTGGGGGCCCA-3’) 
the addition of the Taq enzyme leads to the extension and incorporation 
of the primers, resulting in a nicked circular strands. The addition of 
DpnI to the reaction causes the digestion of the methylated, non mutated 
DNA template. DpnI treated DNA from sample reaction was transferred 
to 50 l of super-competent cells. After transformation, the super-
competent cells repair the nicks in the mutated plasmid. 
 
Cell culture and transfection. 
 
H1299, U2OS, HEK293T, MEFs p53-/MDM2-, T11HT and T1 cell 
lines were maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum and grown at 37°C in 
humidified atmosphere of 5% CO2 . 
Transfections were performed as described below. 
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Cell Line Plate diametr # Cells DNA Reagent DNA/Reagent 
H1299 
35 mm 2.5x10
5
 2g 
Lipofectamine 1:3 
60 mm 5x10
5
 5g 
U20S 
35 mm 2.5x10
5
 2g 
Lipofectamine 2000 1:1,5 
60 mm 5x10
5
 5g 
HEK 293T 
35 mm 3.3x10
5
 2g 
Lipofectamine 1:3 
60 mm 6.5x10
5
 5g 
MEFs 
35 mm 2.5x10
5
 2g 
Lipofectamine 2000 1:3 
60 mm 5x10
5
 5g 
 
The cells were transfecting following the manufacturer’ s instructions.  
The total amount of transfected DNA was kept constant by using the 
“empty” expression vector when necessary. 
 
SDS-Page and Western Blot analysis. 
 
After transfection, cells were lysed in RIPA Buffer (50 mMTris-HCl pH 
7.5, 5 mM EDTA, 150 mM NaCl, 1% NP-40, 1 mM 
phenylmethylsulfonyl fluoride, 0.5% sodium deoxycholate, and protease 
inhibitors. Cell lysates were incubated on ice for 40 minutes, and the 
extracts were centrifuged at 13,000 rpm for 15 minutes to remove cell 
debris. Protein concentrations were determined by the Bio-Rad protein 
assay. After the addition of 2x Laemmli buffer (SIGMA), the samples 
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were boiled at 100°C for 5 minutes and resolved by SDS-polyacrylamide 
gel electrophoresis. Proteins were transferred to a polyvinylidene 
difluoride membrane (Millipore) probed with the primary antibodies 
described in the results (2 hours at room temperature or over night at 
4°C), followed by incubation with the horseradish peroxidase secondary 
antibodies (1 hour at room temperature). Proteins were visualized by 
enhanced chemiluminescence method  (ECL) (GE-Healthcare).  
 
Coimmunoprecipitation Assay. 
 
Coimmunoprecipitations were carried out in U2OS cells. 5.0 x10
5 
cells 
were plated in 60 mm dishes and transfected with 1:1 ratio of TBP-1 and 
various ARF constructs. Cells were harvested 24 hours post-transfection, 
lysed in IBP buffer (150 mM NaCl, 50 mM Tris-HCl, 0.5% Nonidet P-
40, , 5mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride 
(PMSF) and protease inhibitors) and then incubated overnight at 4°C 
with 2 g of anti-ARF (Santa Cruz sc-8613) or with 2g of monoclonal 
anti-TBP-1 (BIOMOL PW8770). The following day protein-A agarose 
(Roche) or protein G-sepharose (Amersham Biosciences) beads were 
added for 3 hours at 4
o 
C. The beads were collected by centrifugation, 
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and the immunoprecipitates were washed three times with IBP buffer (4 
°C), solubilized in Laemmli buffer, loaded on 8 or 12% SDS-Page and 
analyzed by immunoblotting with anti-TBP-1 antibody or anti-ARF 
antibody. 
 
siRNA of TBP-1. 
 
A duplex  siRNA oligomer designed to target human TBP-1 was 
obtained by MWG Biotech according to Corn et al. (2003). The siRNA 
sequence for TBP-1 used is 5’-AACAAGACCCUGCCGUACCUU-3’, 
corresponding to position 204 in the PSMC3 mRNA. As negative 
control a siRNA targeting a sequence firefly luciferase mRNA was used. 
H1299 cells were transfected with Hyperfect (Quiagen) according to the 
manufacturer’s instructions applying siRNA duplex at final 
concentrations of 10 M. Western blots were performed with anti-
MDM2 (Calbiochem OP115), anti-Itch (BD-Clontech 611198), anti -
tubulin (Santa Cruz sc-9104), anti-B23 (Zymed FC61991), anti-p21 
(Santa Cruz sc-397), anti actin (Santa Cruz sc-1616), anti-ARF and anti-
TBP-1. 
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siRNA of MDM2. 
 
A twenty-one nucleotide RNA targeting human MDM2 mRNA 5’-
AAGCCAUUGCUUUUGAAGUUA-3’ and a siRNA targeting a 
sequence firefly luciferase-mRNA, used as control, were chemically 
synthesized by MWG Biotech. U2OS cells were transfected with 
Hyperfect (Quiagen) according to the manufacturer’s instructions using 
siRNA duplex at final concentrations of 10 nM. Western blots were 
performed with anti-MDM2, anti-TBP-1 and anti-pAKT Ser473 (Cell 
Signalling 9271). 
 
Subcellular localization assay.  
 
U2OS were plated in 35mm dishes and grown on micro cover glasses 
(BDH). Twenty four hours after transfection with the appropriate vectors 
(see Results), cells were washed with phosphate-buffered saline (PBS) 
and fixed with 4% paraformaldehyde (Sigma-Aldrich), for 15 minutes. 
Cells were then washed twice with PBS and permeabilized in 0.1% 
Triton X-100 for 10 minutes at room temperature. After the 
permeabilization cells were incubated in blocking buffer solution for 15 
minutes (PBS containing 5% of FBS) and then incubated in blocking 
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buffer supplemented by 0.5% Tween-20, containing the primary 
antibody (anti-FLAG 1:2000 (M2-Sigma) (to determine subcellular 
localization of ARF FLAG and ARF FLAG1-39) for 30 minutes at room 
temperature. Following extensive washing in PBS, fixed cells were 
incubated with the appropriate fluorochrome-conjugated secondary 
antibody for a further 30 minutes at room temperature. In details, anti-
Flag was visualized with anti-Cy3-conjugated anti-mouse 
(ImmunoResearch). After PBS washing, the cells were incubated with 
DAPI (4’,6’-diamidino-2-phenylindole) 10 mg/ml [Sigma]) for 3 
minutes. Glasses were then washed in PBS, mounted with Moviol 
(Sigma) and examined under a fluorescence microscope (Nikon). Images 
were digitally processed by Adobe Photoshop software. 
 
Treatment with proteasome and lysosomes inhibitors. 
 
U2OS cells were seeded into two 60-mm plates and transfected with 
pcDNA ARF39-132. The following day, each plate was split into two 
aliquots to obtain four 35 mm plates and incubated to allow the adhesion. 
Subsequently, each plate was treated for 6 hours with 50 M ALLnL 
(Sigma), 50 M MG132 (Sigma) and with 0.1% dimethyl sulfoxide 
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(Sigma) as control. Cell lysates were collected and probed with anti-ARF 
and anti-actin antibodies. 
293T cells were treated for 6 hours with proteasome (50 M ALLnL, 25 
M MG132) and lysosome inhibitors (100 nM Bafilomycin, 25 M 
NH4Cl, 200 M Cloroquine). Cell lysates were probed with anti-ARF 
and anti-actin antibodies. 
 
Decay rate analysis. 
 
U2OS cells were transfected with the plasmids decribed in the Results. 
Twelve hours after transfection, the cells were trypsinized and reseeded 
in smaller wells corresponded to the different time points. Twenty-four 
hours after transfection, cycloheximide (Sigma) was added to the 
medium at a final concentration of 80 g/ml, and cells were harvested at 
the indicated time points. Total cell extract were prepared as described 
above. Cell extracts were probed, in Western blot, with anti-ARF 
antibody and, as control, with anti-actin antibody. 
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In vitro protein degradation assay. 
 
Reticulocyte lysate translated proteins (kit Promega), were treated for 1 
or 3 h at 37ºC with or without 1 mg of 20S proteasome (Sigma) in 
degradation buffer (20mM Tris-Hcl pH 7, 0.2M. NaCl, 10mM MgCl2, 
1mM dithiothreitol) with or without 50 M MG132. 
Translated p14ARF or p14ARF39-132 were also pre-incubated for 30 
minutes on ice, with in vitro translated TBP-1 before the addition of the 
20S proteasome. Reaction was stopped by the addition of Laemmli 
Buffer and samples were analysed by Western blot as previously 
described.  
 
Treatment of the cells with PI3K inhibitors. 
 
T11HT and T1 cells were plated in 35 mm dishes. 24 hours after the 
plating, cells were treated with Wortmannin (Calbiochem) at the 
concentration of 100, 200 and 300 nM for 1 hour and with LY294002 
(Calbiochem) at the concentration of 10, 50 and 100 M for 15 minutes. 
Total cell extracts were prepared as described above and samples were 
analyzed by Western blot. 
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Treatment of the cells with insulin. 
 
U2OS cells were starved for four hours in serum free medium and then 
stimulated with insulin at the concentration of 10 ng/ml for 5, 10, 20, 30 
and 40 minutes. Cells were harvested and analyzed by Western blot with 
antibodies indicated in the Results. 
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